var title_f4_24_4480="Tracheomalacia by CT";
var content_f4_24_4480=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F52229&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F52229&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 532px\">",
"   <div class=\"ttl\">",
"    Tracheomalacia by computed tomography (CT)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 512px; height: 175px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Axial CT airway imaging in A) inspiration and B) expiration and C) dynamic expiration. There is excessive tracheal collapsibility on expiration. Note that in some cases the collapse can not be demonstrated on end- exhalation, but is much more prominent on dynamic imaging. Reliance on in- and expiratory imaging alone can be a source for false negative examinations.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. P. Boiselle.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_24_4480=[""].join("\n");
var outline_f4_24_4480=null;
var title_f4_24_4481="Nitroxoline: International drug information";
var content_f4_24_4481=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"15\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Nitroxoline: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4369847\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Cysto-Saar (DE);",
"     </li>",
"     <li>",
"      Nibiol (FR);",
"     </li>",
"     <li>",
"      Nicene N (ZA)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F2522861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Miscellaneous",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F2522862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Acute and chronic uncomplicated lower urinary tract infection",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F2522864\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: Oral: 240-750 mg/day in divided doses before meals",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821130\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F2522865\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet: 100 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10476 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-183.1.191.153-340D2F8564-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_24_4481=[""].join("\n");
var outline_f4_24_4481=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4369847\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2522861\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2522862\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2522864\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821130\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2522865\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10476\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10476|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_24_4482="Patient information: Cold sores (oral herpes) (The Basics)";
var content_f4_24_4482=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15785\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/55/881\">",
"         Cold sores (fever blisters)",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?21/25/21906\">",
"         Patient information: Genital herpes (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Cold sores (oral herpes) (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/cold-sores-oral-herpes-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H13395503\">",
"      <span class=\"h1\">",
"       What are cold sores?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Cold sores are painful blisters that form on or near the lips and inside the mouth. They are caused by an infection with a virus called &ldquo;herpes simplex virus.&rdquo; There are two types of herpes virus. Type 1 causes most cases of cold sores. Type 2, also called genital herpes, usually affects the penis or vagina.",
"     </p>",
"     <p>",
"      Cold sores are also known as fever blisters.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13395510\">",
"      <span class=\"h1\">",
"       What are the symptoms of cold sores?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The symptoms are different depending on whether it is the first time a person is getting cold sores. The first attack of cold sores usually happens during childhood.",
"     </p>",
"     <p>",
"      The",
"      <strong>",
"       first",
"      </strong>",
"      time a person gets cold sores, the symptoms can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Painful blisters on the lips, mouth, nose, or throat, which eventually pop and form scabs (",
"        <a class=\"graphic graphic_picture graphicRef80183 \" href=\"UTD.htm?0/55/881\">",
"         picture 1",
"        </a>",
"        )",
"       </li>",
"       <li>",
"        Mouth and throat pain",
"       </li>",
"       <li>",
"        Swelling in the neck",
"       </li>",
"       <li>",
"        Fever, body aches, and feeling ill",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      After the first time, pain and blisters can come back, but the other symptoms do not usually happen again. Plus, the symptoms are usually milder and don&rsquo;t last as long.",
"     </p>",
"     <p>",
"      When symptoms first occur, they can last 10 to 14 days. Later, if they come back, they can last 8 days or less. Some people can tell when their cold sores are going to come back. They feel pain, burning, tingling, or itching on their lips about a day before blisters form.",
"     </p>",
"     <p>",
"      People sometimes confuse cold sores with canker sores. But canker sores are different. Canker sores are painful red or white sores, but they do not usually form blisters or scab over. Canker sores can form in your mouth and on your tongue. Doctors do not know what causes canker sores.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13395517\">",
"      <span class=\"h1\">",
"       Why did I get a cold sore?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The virus that causes cold sores spreads easily from person to person. You might have caught it from an infected person if the two of you shared a fork or knife, kissed, or had some other type of close contact.",
"     </p>",
"     <p>",
"      People who give oral sex to people with genital herpes can get cold sores on their mouth.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13395524\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;See your doctor or nurse if your symptoms are severe or if they keep you from swallowing fluids.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13395531\">",
"      <span class=\"h1\">",
"       Is there a test for cold sores?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes, your doctor or nurse can take some fluid from a cold sore and check it for the herpes virus. But that is not usually necessary. In most cases, doctors can diagnose cold sores just by looking at them.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13395538\">",
"      <span class=\"h1\">",
"       How are cold sores treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most people need treatment the first time they have cold sores. But people who have had cold sores before or who have mild symptoms do not always need treatment. For those who do need treatment, it can come in two forms:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Some treatments help the body fight the herpes virus. These are called &ldquo;antiviral medicines.&rdquo; They reduce symptoms and shorten the amount of time symptoms last. These medicines work best if they are started as soon as possible after symptoms begin. Most people do not need these medicines.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Some treatments treat just the pain and discomfort of cold sores without affecting the virus. These treatments include pain-relieving pills and gels that go on the mouth. Many of these treatments are sold without a prescription.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Treatments can help ease the symptoms of cold sores, but no treatment can cure cold sores for good. Once you have the virus that causes cold sores, you will have it for the rest of your life. That means that cold sores can keep coming back. Luckily, symptoms usually get milder with time.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13395545\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own to feel better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Some people find that pain goes down if they suck on ice or popsicles.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13395552\">",
"      <span class=\"h1\">",
"       Can cold sores be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you have frequent, painful outbreaks of cold sores, your doctor or nurse might give you an antiviral medicine to take every day to prevent new symptoms. But most people do not need this kind of treatment.",
"     </p>",
"     <p>",
"      If you have never had cold sores, you can also reduce the chances of getting them by avoiding close contact with people who have them. To protect other people,",
"      <strong>",
"       when you have cold sores",
"      </strong>",
"      do NOT:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Kiss anyone",
"       </li>",
"       <li>",
"        Share forks, knives, spoons, glasses, towels, lip balm, or razors",
"       </li>",
"       <li>",
"        Give anyone oral sex",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13395678\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/25/21906?source=see_link\">",
"       Patient information: Genital herpes (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?4/24/4482?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15785 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-14.112.150.12-587BC34546-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_24_4482=[""].join("\n");
var outline_f4_24_4482=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13395503\">",
"      What are cold sores?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13395510\">",
"      What are the symptoms of cold sores?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13395517\">",
"      Why did I get a cold sore?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13395524\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13395531\">",
"      Is there a test for cold sores?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13395538\">",
"      How are cold sores treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13395545\">",
"      Is there anything I can do on my own to feel better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13395552\">",
"      Can cold sores be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13395678\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15785\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/55/881\">",
"      Cold sores (fever blisters)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/25/21906?source=related_link\">",
"      Patient information: Genital herpes (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_24_4483="Ocriplasmin: Patient drug information";
var content_f4_24_4483=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ocriplasmin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/32/27139?source=see_link\">",
"     see \"Ocriplasmin: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F15898399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Jetrea&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F16058870\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4131848",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat vitreomacular adhesion (VMA).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F16058869\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4131849",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ocriplasmin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F16058873\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F16058874\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3568982",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Eye pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698044",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Eye infection.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698045",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Eye irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697912",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blurred eyesight. Use care when driving or doing other tasks that call for clear eyesight.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F16058875\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F16058872\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695993",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into the eye.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F16058876\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 87799 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-042A3B073A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_24_4483=[""].join("\n");
var outline_f4_24_4483=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15898399\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16058870\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16058869\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16058873\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16058874\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16058875\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16058872\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16058876\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/32/27139?source=related_link\">",
"      Ocriplasmin: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_24_4484="Focal organizing pneumonia CT";
var content_f4_24_4484=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F87705&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F87705&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 511px\">",
"   <div class=\"ttl\">",
"    Focal organizing pneumonia CT",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 491px; height: 367px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Computed tomography image of focal organizing pneumonia manifest as a right upper lobe solitary spiculated mass with irregular margins, cavitation, and thickening of the adjacent pleura, but without air bronchogram or mediastinal lymphadenopathy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_24_4484=[""].join("\n");
var outline_f4_24_4484=null;
var title_f4_24_4485="Juvenile spring eruption 2";
var content_f4_24_4485=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F68969&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F68969&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Juvenile spring eruption",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 409px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythematous papules and vesicles are present on the ear of this young girl with juvenile spring eruption.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Bernard Cohen, MD, Dermatlas; file://www.dermatlas.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_24_4485=[""].join("\n");
var outline_f4_24_4485=null;
var title_f4_24_4486="Nephrology pattern 14 answer";
var content_f4_24_4486=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F55195&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F55195&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nephrology pattern 14 answer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 243px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Glomerular amyloidosis. Light micrograph of glomerular amyloidosis shows nodular, amorphous material (arrows) extending from the mesangium into the capillary loops and narrowing or closing the capillary lumens. The nodules are more amorphous than those seen in diabetic nephropathy but demonstration of amyloid fibrils on electron microscopy or demonstrating green birefringence on Congo red staining is required to confirm the diagnosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_24_4486=[""].join("\n");
var outline_f4_24_4486=null;
var title_f4_24_4487="Definition and consequences of sleep deprivation";
var content_f4_24_4487=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Definition and consequences of sleep deprivation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/24/4487/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/24/4487/contributors\">",
"     Mark R Pressman, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/24/4487/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/24/4487/contributors\">",
"     Robert C Basner, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/24/4487/contributors\">",
"     Ruth Benca, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/24/4487/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/24/4487/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/24/4487/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical wisdom and supporting research suggest that most people require approximately eight hours of sleep nightly [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4487/abstract/1\">",
"     1",
"    </a>",
"    ]. However, there appears to be considerable variation around the mean, with many people claiming to need only four to six hours of sleep. The definition and consequences of sleep deprivation are reviewed here. Sleep deprivation is distinguished from insomnia separately (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/41/4758?source=see_link&amp;anchor=H7#H7\">",
"     \"Overview of insomnia\", section on 'Differential diagnosis'",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17396905\">",
"    <span class=\"h1\">",
"     DEFINITION OF SLEEP DEPRIVATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sleep deprivation exists when sleep is insufficient to support adequate alertness, performance, and health, either because of reduced total sleep time or fragmentation of sleep by brief arousals. Acute sleep deprivation refers to no sleep or a reduction in the usual total sleep time, usually lasting one or two days. In contrast, chronic sleep deprivation (also called sleep restriction) exists when the individual routinely sleeps less than required for optimal functioning.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11332005\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;More than one-third of individuals report sleeping less than seven hours per night on weekdays or workday nights, according to the 2005 to 2008 National Health and Nutrition Examination Survey [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4487/abstract/2\">",
"     2",
"    </a>",
"    ]. This was most common among individuals 20 to 59 years of age and among non-Hispanic blacks. Individuals who reported sleeping fewer than seven hours per night were more likely to report difficulty concentrating than individuals who reported sleeping seven to nine hours per night (29 versus 19 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17396297\">",
"    <span class=\"h1\">",
"     CAUSES OF SLEEP DEPRIVATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sleep deprivation may be a consequence of an insufficient amount of sleep",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    poor quality sleep.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17396927\">",
"    <span class=\"h2\">",
"     Insufficient quantity of sleep",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is difficult to determine what constitutes a normal quantity of sleep for a given individual. One approach involves determining how long a patient would sleep if left to awaken spontaneously. An alternative approach involves determining how alert the patient feels after different durations of sleep. Alertness is normal if the patient wakes feeling refreshed and is capable of moving through the day feeling alert without effort, even when placed in boring or monotonous situations. This sense of easy alertness should be distinguished from alertness that exists when the individual feels pressure, since the latter may persist despite sleep deprivation.",
"   </p>",
"   <p>",
"    Once the normal quantity of sleep for an individual (ie, the nightly sleep quota) has been determined, the sleep deficit can be estimated as illustrated by the following example. If a person who has a nightly sleep quota of eight hours sleeps only six hours, there is a two hour sleep deficit. That sleep deficit is carried over to the next day. A 14 hour sleep debt will accrue after seven days if two hours of sleep are lost nightly, which is nearly equivalent of two full nights without sleep [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4487/abstract/3\">",
"     3",
"    </a>",
"    ]. Cumulative partial sleep deprivation, therefore, can be equivalent of acute total sleep deprivation, but may be much harder for the patient and clinician to recognize [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4487/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A nightly reduction in sleep below the normal quantity of sleep for an individual may not have clear effects on performance or subjective sleepiness if the total sleep is not six hours or less. Sensitive instruments like the psychomotor vigilance test may detect decrements, but individuals may otherwise appear to adapt to the sleep loss as long as the nightly sleep duration remains in the range of six to nine hours. Short naps have been reported to restore full alertness [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4487/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A return to normal sleep quotas after a period of sleep deprivation results in rebound sleep. This means that deep sleep and rapid eye movement (REM) sleep will appear in quantities higher than expected for several nights after normal sleep duration has resumed if these stages of sleep had been reduced below their usual quantities during sleep deprivation. It appears that deep sleep will rebound first and REM second, but this may be an artifact of experimental methods that did not allow sufficient time in bed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17396963\">",
"    <span class=\"h2\">",
"     Poor quality sleep",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is possible for an individual to sleep eight or more hours and still be sleep deprived. In such cases, the sleep deprivation is usually due to disturbances in the quality of sleep [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4487/abstract/6\">",
"     6",
"    </a>",
"    ]. Sleep quality is determined by the number of arousals (or awakenings) from sleep during the night, as well as the percentage, duration, and type of sleep stages. As few as five arousals per hour of sleep can result in daytime sleepiness",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    performance deficits, even after a single night of disruption [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4487/abstract/7\">",
"     7",
"    </a>",
"    ]. Patients are unaware of the arousals, in part because their duration is only seconds and then the individual returns to the same sleep stage that was interrupted. Arousals are usually due to sleep disorders (eg, sleep apnea, periodic leg movements), but they may also occur spontaneously.",
"   </p>",
"   <p>",
"    In one study, performance deficits equivalent to 40 to 60 hours of total sleep deprivation developed after sleep was experimentally disrupted 60 times per hour for two consecutive days, [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4487/abstract/8\">",
"     8",
"    </a>",
"    ]. Even repetitive administration of acoustic tones that fail to result in electroencephalographic arousal will result in objectively measured increases in daytime sleepiness and measurable alterations in mood [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4487/abstract/7\">",
"     7",
"    </a>",
"    ]. Experimental manipulations of sleep quality suggest that sleep disorders such as sleep apnea, which cause significant sleep fragmentation, result in severely sleep-deprived patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CONSEQUENCES OF SLEEP DEPRIVATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sleep deprivation is associated with a variety of adverse consequences, which may not be appreciated by patients or clinicians [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4487/abstract/9\">",
"     9",
"    </a>",
"    ]. These consequences include reduced performance, increased risk for accidents and death, and detrimental effects on both psychological and physical health.",
"   </p>",
"   <p>",
"    A powerful drive for sleep that is not always under the control of the individual is probably responsible for the adverse consequences of sleep deprivation. The drive allows sleep to intrude into wakefulness for only a few seconds (ie, microsleeps) whenever there is a lack of physical activity, such as driving. Even such brief periods of sleep can result in serious or catastrophic consequences. As an example, a car driving 60 MPH will travel more than 250 feet during a three second microsleep and, if the road curves or a car stops in front of the driver, a serious accident may occur [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4487/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17396304\">",
"    <span class=\"h2\">",
"     Individual responses to sleep deprivation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effects of sleep deprivation vary significantly among individuals, but are quite stable within individuals. Such effects are independent of the amount of prior sleep loss.",
"   </p>",
"   <p>",
"    The ability to predict who will or will not be able to tolerate partial or total sleep deprivation has many practical applications, including shift work and sustained military operations [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4487/abstract/11\">",
"     11",
"    </a>",
"    ]. Vulnerability or resistance to sleep deprivation has been shown to have trait-like qualities, suggesting a genetic predisposition. Candidate genes that may predict vulnerability to sleep loss have been identified. However, they have not yet proven to be reliable enough to be used as a screening test [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4487/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Cognitive deficits and mental status",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sleep deprivation can result in significant changes in cognitive functioning. As an example, total sleep deprivation is consistently associated with decrements in tasks that require sustained attention, such as reaction time [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4487/abstract/13\">",
"     13",
"    </a>",
"    ]. Such deficits in sustained attention may underlie the deficits in memory and decision-making that are often reported following total sleep deprivation. In contrast, many aspects of executive functioning, long considered vulnerable to sleep deprivation, are unaffected after 51 hours of total sleep deprivation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4487/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sleep deprivation may result in a mental status that resembles depression or anxiety, with patients reporting poor mood, irritability, low energy, decreased libido, poor judgment, and other signs of psychologic dysfunction. These symptoms often disappear when normal sleep is restored.",
"   </p>",
"   <p>",
"    Epidemiologic and clinical studies suggest that sleep deprivation resulting from syndromes such as sleep-disordered breathing are associated with measurable neuropsychological deficits. For example, cross-sectional data from the Wisconsin Sleep Cohort Study, a population-based investigation of sleep apnea in working age men and women, indicate that individuals with higher numbers of apneas or hypopneas per hour of sleep (apnea-hypopnea index) test lower on neurocognitive measures of motor skills, attention, and information processing than do individuals with few or no respiratory events during sleep [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4487/abstract/16\">",
"     16",
"    </a>",
"    ]. Interestingly, no relationship was evident between apnea-hypopnea index and memory.",
"   </p>",
"   <p>",
"    The neurobehavioral effect of partial or total sleep deprivation was directly evaluated in a prospective study of 48 patients randomly assigned to four, six, or eight hours of sleep per night for 14 days, or a three-night period without sleep [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4487/abstract/3\">",
"     3",
"    </a>",
"    ]. All subjects underwent neurocognitive and polysomnographic testing. Restriction of sleep to six hours or less per night produced cognitive performance deficits equivalent to two nights of total sleep deprivation. For subjects in all groups, wakefulness in excess of 16 hours predicted performance lapses. Of note, subjects appeared to be largely unaware of these increasing cognitive deficits, based on their own assessments.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Crashes and workplace errors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Excessive sleepiness is the second leading cause of car crashes and a major cause of truck crashes in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4487/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. In addition, many major catastrophes, including the Three Mile Island and Chernobyl nuclear power plant disasters, the Exxon Valdez oil spill, and the Space Shuttle Challenger disaster have been attributed to the poor judgment of sleep-deprived workers [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4487/abstract/20\">",
"     20",
"    </a>",
"    ]. Sleepiness-related incidents cost billions of dollars each year [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4487/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/51/38710?source=see_link\">",
"     \"Performance and safety risks of sleep deprivation and sleep disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Quality of life",
"    </span>",
"    &nbsp;&mdash;&nbsp;In our experience, we have found that sleep-deprived patients frequently report that their quality of life suffers as a result of the sleep deprivation. They often cut back on activities they enjoy, claiming that they do not have enough energy to perform the activity. Inappropriate drowsiness and unplanned naps may be a source of embarrassment and friction, both at home and at work. Patients who fall asleep at work or whose productivity suffers due to sleepiness may be reprimanded, denied advancement, or fired. Falling asleep at home may cause resentment and marital discord.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is evidence that sleep deprivation may be associated with an increased risk of mortality. In one observational study, individuals who slept fewer than four hours or more than ten hours had an increased rate of mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4487/abstract/22\">",
"     22",
"    </a>",
"    ]. A more recent observational study reported that men who slept less than six hours had a risk for mortality that was four times greater than the risk for mortality among normal sleepers [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4487/abstract/23\">",
"     23",
"    </a>",
"    ]. Finally, an animal model of sleep deprivation found that approximately two to three weeks of continuous sleep deprivation resulted in death.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17396880\">",
"    <span class=\"h2\">",
"     Circadian factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Circadian rhythms (ie, biologic rhythms) are physiological parameters that vary in predictable ways over 24 hours. The sleep-wake cycle is one such rhythm. The core body temperature is another 24 hour rhythm that may provide the internal timing for sleep and wakefulness. Sleep typically occurs when the temperature is declining, whereas wakefulness usually occurs when the temperature is rising. During sleep deprivation (eg, due to shift work or jet lag), sleep and wakefulness may become disconnected from their proper temperature associations. If this occurs, the body may be physiologically prepared for sleep during the daytime, when the individual should be alert and active. The individual may be unable to sleep at socially acceptable times",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    may have to arise before a biologically optimal time. This may result in a reduction of total sleep time until the individual&rsquo;s sleep-wake rhythm is realigned with core body temperature. Such patients may be sleepy regardless of the prior quantity and quality of sleep [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4487/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Respiratory physiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sleep deprivation has been reported to depress ventilatory responses to hypercapnia and hypoxia in otherwise normal subjects, suggesting that sleep deprivation could contribute to hypoventilation in hospitalized patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4487/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. However, these findings have not been universal, suggesting that such results may be an artifact of uncontrolled factors or environmental influences [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4487/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Respiratory muscle endurance can also be affected by sleep deprivation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4487/abstract/29\">",
"     29",
"    </a>",
"    ]. Specifically, inspiratory muscle endurance is significantly decreased, while end-tidal PCO2 is increased. Effects of sleep deprivation on cardiopulmonary functioning may be much greater in patients with existing disease, including those with chronic obstructive pulmonary disease (COPD) or neuromuscular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4487/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/52/9030?source=see_link\">",
"     \"Treatment of sleep-disordered breathing in COPD\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/6/5222?source=see_link\">",
"     \"The effect of sleep in patients with neuromuscular and chest wall disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Cardiovascular",
"    </span>",
"    &nbsp;&mdash;&nbsp;The duration of sleep may be inversely associated with blood pressure and coronary artery calcification:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a prospective cohort study that followed 535 young adults (age 18 to 30) for 15 years, a shorter duration of sleep was associated with a greater likelihood of developing hypertension, even after adjusting for possible confounders (adjusted odds ratio 1.37, 95% CI 1.05-1.78) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/24/4487/abstract/31\">",
"       31",
"      </a>",
"      ]. Sleep duration was measured by wrist actigraphy, while hypertension was defined as a systolic blood pressure &ge;140 mmHg, a diastolic blood pressure &ge;90 mmHg, or antihypertensive medication use.",
"     </li>",
"     <li>",
"      In a prospective cohort study of 495 healthy individuals, a longer sleep duration was associated with a significantly reduced incidence of coronary artery calcification when the sleep duration was measured by actigraphy, but not when the sleep duration was determined by self-report [",
"      <a class=\"abstract\" href=\"UTD.htm?4/24/4487/abstract/32\">",
"       32",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30410?source=see_link\">",
"       \"Diagnostic and prognostic implications of coronary artery calcification detected by computed tomography\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Sleep deprivation may also be associated with other adverse cardiovascular outcomes. In a cross-sectional study of 30,397 adults, the prevalence of myocardial infarction, angina, or stroke was higher among individuals who slept &le;5 hours per night than among those who slept seven hours per night (adjusted odds ratio 2.2, 95% CI 1.78-2.71) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4487/abstract/33\">",
"     33",
"    </a>",
"    ]. There was a smaller increase in the prevalence of events among patients who slept longer than seven hours per night. The overall prevalence of the cardiovascular outcomes in the population studied was 7 percent. An important limitation of this study is that sleep duration was self-reported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Immune function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sleep deprivation can adversely affect immune function. As an example, complete sleep deprivation of rats for several weeks results in death [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4487/abstract/34\">",
"     34",
"    </a>",
"    ]. The cause of death in this setting is a total breakdown of host defenses via immunosuppression, producing severe septicemia [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4487/abstract/35\">",
"     35",
"    </a>",
"    ]. Sleep deprivation can also interfere with the immune responses to respiratory viruses administered nasally in rats, even though they had been previously inoculated against the particular respiratory virus [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4487/abstract/36\">",
"     36",
"    </a>",
"    ]. In humans, partial or total sleep deprivation results in increased plasma levels of soluble tumor necrosis factor (TNF)-alpha and interleukin (IL)-6, both of which are involved in immune regulation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4487/abstract/37-39\">",
"     37-39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Appetite",
"    </span>",
"    &nbsp;&mdash;&nbsp;The proportion of adults in the United States sleeping less than seven hours per night has increased from 16 to 37 percent over the past 40 years [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4487/abstract/40\">",
"     40",
"    </a>",
"    ], a lifestyle change that may have negative metabolic consequences. This was illustrated in a study of 12 healthy, normal weight, adult men who underwent two nights of sleep restriction (four hours per night) and two nights of sleep extension (10 hours per night) in a randomized order, spaced six weeks apart with controlled conditions of caloric intake and physical activity [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4487/abstract/41\">",
"     41",
"    </a>",
"    ]. Sleep restriction, when compared to sleep extension, was associated with a decrease in serum leptin (an anorexigenic hormone), an increase in serum ghrelin (an orexigenic hormone), and increased hunger and appetite (in particular for calorie-dense foods with high carbohydrate content). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/23/16758?source=see_link\">",
"     \"Ghrelin\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These findings suggest that inadequate sleep could result in excessive eating and obesity, although this has not yet been reported. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/21/3418?source=see_link&amp;anchor=H11#H11\">",
"     \"Etiology and natural history of obesity\", section on 'Sleep deprivation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1262559\">",
"    <span class=\"h1\">",
"     FATIGUE MITIGATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The best strategy to alleviate fatigue is to extend total sleep time or eliminate sleep fragmentation. Patients might be advised to sleep-in for several days in a row, sleeping until they awaken spontaneously feeling alert and are able to pursue their daily activities without additional efforts. Strategic napping may reduce fatigue if the patient is unable to extend their nightly sleep; short, 15 to 20 minute naps may provide several additional hours of alertness. Physical activity, caffeine, bright light, or prescription analeptics may be effective if napping is not possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17396342\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sleep deprivation exists when sleep is insufficient to support adequate alertness, performance, and health, either because of reduced total sleep time or fragmentation of sleep by brief arousals. Acute sleep deprivation refers to no sleep or a reduction in the usual total sleep time, usually lasting for one or two days. In contrast, chronic sleep deprivation (also called sleep restriction) exists when the individual routinely sleeps less than required for optimal functioning. (See",
"      <a class=\"local\" href=\"#H17396905\">",
"       'Definition of sleep deprivation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sleep deprivation may be a consequence of an insufficient amount of sleep",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      poor quality sleep. (See",
"      <a class=\"local\" href=\"#H17396297\">",
"       'Causes of sleep deprivation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sleep deprivation is associated with a variety of adverse consequences, which are often not appreciated by patients or clinicians. These consequences vary significantly among individuals, but are quite stable within individuals. They include reduced performance, increased risk for accidents and death, and detrimental effects on both psychological and physical health. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Consequences of sleep deprivation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4487/abstract/1\">",
"      Bonnet MH, Arand DL. We are chronically sleep deprived. Sleep 1995; 18:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4487/abstract/2\">",
"      Centers for Disease Control and Prevention (CDC). Effect of short sleep duration on daily activities--United States, 2005-2008. MMWR Morb Mortal Wkly Rep 2011; 60:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4487/abstract/3\">",
"      Van Dongen HP, Maislin G, Mullington JM, Dinges DF. The cumulative cost of additional wakefulness: dose-response effects on neurobehavioral functions and sleep physiology from chronic sleep restriction and total sleep deprivation. Sleep 2003; 26:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4487/abstract/4\">",
"      Carskadon MA, Dement WC. Cumulative effects of sleep restriction on daytime sleepiness. Psychophysiology 1981; 18:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4487/abstract/5\">",
"      Horne J. The end of sleep: 'sleep debt' versus biological adaptation of human sleep to waking needs. Biol Psychol 2011; 87:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4487/abstract/6\">",
"      Martin SE, Engleman HM, Deary IJ, Douglas NJ. The effect of sleep fragmentation on daytime function. Am J Respir Crit Care Med 1996; 153:1328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4487/abstract/7\">",
"      Martin SE, Wraith PK, Deary IJ, Douglas NJ. The effect of nonvisible sleep fragmentation on daytime function. Am J Respir Crit Care Med 1997; 155:1596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4487/abstract/8\">",
"      Bonnet MH. Effect of sleep disruption on sleep, performance, and mood. Sleep 1985; 8:11.",
"     </a>",
"    </li>",
"    <li>",
"     Johnson, LC. Sleep deprivation and performance. In: Biological Rhythms, Sleep and Performance, Webb, WB (Eds), John Wiley and Sons, New York 1982. p.111.",
"    </li>",
"    <li>",
"     Dinges DF, Kribbs NB. Performing while sleeping: effects of experimentally induced sleepiness. In: Sleep, sleepiness, and performance, Monk TH.  (Ed), Wiley &amp; Sons, Chichester, UK 1991. p.97-128.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4487/abstract/11\">",
"      Van Dongen HP, Baynard MD, Maislin G, Dinges DF. Systematic interindividual differences in neurobehavioral impairment from sleep loss: evidence of trait-like differential vulnerability. Sleep 2004; 27:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4487/abstract/12\">",
"      King AC, Belenky G, Van Dongen HP. Performance impairment consequent to sleep loss: determinants of resistance and susceptibility. Curr Opin Pulm Med 2009; 15:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4487/abstract/13\">",
"      Lim J, Dinges DF. A meta-analysis of the impact of short-term sleep deprivation on cognitive variables. Psychol Bull 2010; 136:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4487/abstract/14\">",
"      Tucker AM, Whitney P, Belenky G, et al. Effects of sleep deprivation on dissociated components of executive functioning. Sleep 2010; 33:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4487/abstract/15\">",
"      Killgore WD, Killgore DB, Day LM, et al. The effects of 53 hours of sleep deprivation on moral judgment. Sleep 2007; 30:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4487/abstract/16\">",
"      Kim HC, Young T, Matthews CG, et al. Sleep-disordered breathing and neuropsychological deficits. A population-based study. Am J Respir Crit Care Med 1997; 156:1813.",
"     </a>",
"    </li>",
"    <li>",
"     Mitler, MM, Dinges, DF, Dement, WC. medicine, public policy, and public Health. In: Principles and Practice of Sleep Medicine, 2nd, Kryger, MH, Roth, T, Dement, WC (Eds), WB Saunders, Philadelphia 1994. p.453.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4487/abstract/18\">",
"      Summala H, Mikkola T. Fatal accidents among car and truck drivers: effects of fatigue, age, and alcohol consumption. Hum Factors 1994; 36:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4487/abstract/19\">",
"      Pack AI, Maislin G, Staley B, et al. Impaired performance in commercial drivers: role of sleep apnea and short sleep duration. Am J Respir Crit Care Med 2006; 174:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4487/abstract/20\">",
"      Mitler MM, Carskadon MA, Czeisler CA, et al. Catastrophes, sleep, and public policy: consensus report. Sleep 1988; 11:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4487/abstract/21\">",
"      Leger D. The cost of sleep-related accidents: a report for the National Commission on Sleep Disorders Research. Sleep 1994; 17:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4487/abstract/22\">",
"      Kripke DF, Simons RN, Garfinkel L, Hammond EC. Short and long sleep and sleeping pills. Is increased mortality associated? Arch Gen Psychiatry 1979; 36:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4487/abstract/23\">",
"      Vgontzas AN, Liao D, Pejovic S, et al. Insomnia with short sleep duration and mortality: the Penn State cohort. Sleep 2010; 33:1159.",
"     </a>",
"    </li>",
"    <li>",
"     Moore-Ede, MC, Sulzman, FM, Fuller, CA. The Clocks That Time Us, Harvard University Press, Cambridge, MA 1982.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4487/abstract/25\">",
"      White DP, Douglas NJ, Pickett CK, et al. Sleep deprivation and the control of ventilation. Am Rev Respir Dis 1983; 128:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4487/abstract/26\">",
"      Schiffman PL, Trontell MC, Mazar MF, Edelman NH. Sleep deprivation decreases ventilatory response to CO2 but not load compensation. Chest 1983; 84:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4487/abstract/27\">",
"      Bowes, G, Woolf, GM, Sullivan, CE, Phillipson, EA. Effect of sleep fragmentation on ventilatory and arousal response of sleeping dogs to respiratory stimuli. Am Rev Respir Dis 1980; 125:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4487/abstract/28\">",
"      Spengler CM, Shea SA. Sleep deprivation per se does not decrease the hypercapnic ventilatory response in humans. Am J Respir Crit Care Med 2000; 161:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4487/abstract/29\">",
"      Chen HI, Tang YR. Sleep loss impairs inspiratory muscle endurance. Am Rev Respir Dis 1989; 140:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4487/abstract/30\">",
"      Phillips BA, Cooper KR, Burke TV. The effect of sleep loss on breathing in chronic obstructive pulmonary disease. Chest 1987; 91:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4487/abstract/31\">",
"      Knutson KL, Van Cauter E, Rathouz PJ, et al. Association between sleep and blood pressure in midlife: the CARDIA sleep study. Arch Intern Med 2009; 169:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4487/abstract/32\">",
"      King CR, Knutson KL, Rathouz PJ, et al. Short sleep duration and incident coronary artery calcification. JAMA 2008; 300:2859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4487/abstract/33\">",
"      Sabanayagam C, Shankar A. Sleep duration and cardiovascular disease: results from the National Health Interview Survey. Sleep 2010; 33:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4487/abstract/34\">",
"      Rechtschaffen A, Bergmann BM, Everson CA, et al. Sleep deprivation in the rat: X. Integration and discussion of the findings. Sleep 1989; 12:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4487/abstract/35\">",
"      Everson CA. Sustained sleep deprivation impairs host defense. Am J Physiol 1993; 265:R1148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4487/abstract/36\">",
"      Brown R, Pang G, Husband AJ, King MG. Suppression of immunity to influenza virus infection in the respiratory tract following sleep disturbance. Reg Immunol 1989; 2:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4487/abstract/37\">",
"      Vgontzas AN, Zoumakis E, Bixler EO, et al. Adverse effects of modest sleep restriction on sleepiness, performance, and inflammatory cytokines. J Clin Endocrinol Metab 2004; 89:2119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4487/abstract/38\">",
"      Shearer WT, Reuben JM, Mullington JM, et al. Soluble TNF-alpha receptor 1 and IL-6 plasma levels in humans subjected to the sleep deprivation model of spaceflight. J Allergy Clin Immunol 2001; 107:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4487/abstract/39\">",
"      Redwine L, Hauger RL, Gillin JC, Irwin M. Effects of sleep and sleep deprivation on interleukin-6, growth hormone, cortisol, and melatonin levels in humans. J Clin Endocrinol Metab 2000; 85:3597.",
"     </a>",
"    </li>",
"    <li>",
"     National Sleep Foundation. Sleep in America Poll, National Sleep Foundation, Washington, DC, 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4487/abstract/41\">",
"      Spiegel K, Tasali E, Penev P, Van Cauter E. Brief communication: Sleep curtailment in healthy young men is associated with decreased leptin levels, elevated ghrelin levels, and increased hunger and appetite. Ann Intern Med 2004; 141:846.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7715 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.75.47.146-274201436B-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_24_4487=[""].join("\n");
var outline_f4_24_4487=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17396342\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17396905\">",
"      DEFINITION OF SLEEP DEPRIVATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11332005\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17396297\">",
"      CAUSES OF SLEEP DEPRIVATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17396927\">",
"      Insufficient quantity of sleep",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17396963\">",
"      Poor quality sleep",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CONSEQUENCES OF SLEEP DEPRIVATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17396304\">",
"      Individual responses to sleep deprivation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Cognitive deficits and mental status",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Crashes and workplace errors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Quality of life",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17396880\">",
"      Circadian factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Respiratory physiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Cardiovascular",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Immune function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Appetite",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1262559\">",
"      FATIGUE MITIGATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17396342\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30410?source=related_link\">",
"      Diagnostic and prognostic implications of coronary artery calcification detected by computed tomography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/21/3418?source=related_link\">",
"      Etiology and natural history of obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/23/16758?source=related_link\">",
"      Ghrelin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/41/4758?source=related_link\">",
"      Overview of insomnia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/51/38710?source=related_link\">",
"      Performance and safety risks of sleep deprivation and sleep disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/6/5222?source=related_link\">",
"      The effect of sleep in patients with neuromuscular and chest wall disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/52/9030?source=related_link\">",
"      Treatment of sleep-disordered breathing in COPD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_24_4488="Cancer pain management: Use of acetaminophen and nonsteroidal antiinflammatory drugs";
var content_f4_24_4488=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cancer pain management: Use of acetaminophen and nonsteroidal antiinflammatory drugs",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/24/4488/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/24/4488/contributors\">",
"     Russell K Portenoy, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/24/4488/contributors\">",
"     Ebtesam Ahmed, PharmD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/24/4488/contributors\">",
"     Yair Y Keilson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/24/4488/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/24/4488/contributors\">",
"     Janet Abrahm, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/24/4488/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/24/4488/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/24/4488/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Opioid therapy is the first-line approach for moderate or severe chronic pain in populations with active cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/7/30842?source=see_link\">",
"     \"Cancer pain management with opioids: Optimizing analgesia\"",
"    </a>",
"    .) However, the comprehensive management of pain in patients with cancer also requires expertise in the use of the nonopioid analgesics, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    (also known as paracetamol), non-steroidal antiinflammatory agents (NSAIDs), and a group of drugs referred to as \"adjuvant\" analgesics or coanalgesics.",
"   </p>",
"   <p>",
"    A stepwise approach to management of cancer pain that includes both opioid and nonopioid drugs has been codified in the World Health Organization (WHO) \"analgesic ladder\" approach to cancer pain management (",
"    <a class=\"graphic graphic_figure graphicRef63298 \" href=\"UTD.htm?0/45/724\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4488/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Step 1, which represents mild to moderate cancer-related pain, suggests the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      or an NSAID, possibly combined with an adjuvant drug to provide additional analgesia, treat a side effect, or manage a coexisting symptom. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/9/39066?source=see_link\">",
"       \"Cancer pain management: Adjuvant analgesics (coanalgesics)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with moderate or severe pain, and for those who do not achieve adequate relief with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      or a NSAID alone, treatment with a step 2 opioid (conventionally used for moderate pain) or a step 3 opioid (conventionally used for severe pain) is appropriate. On both steps 2 and 3, the use of acetaminophen or an NSAID could be considered, as well as other drugs to enhance analgesia or treat side effects.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The analgesic ladder approach is not an evidence-based guideline, but it provides a framework for the stepwise and systematic approach to managing cancer pain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43704?source=see_link&amp;anchor=H4#H4\">",
"     \"Cancer pain management: General principles and risk management for patients receiving opioids\", section on 'General principles of pain management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The nonopioid analgesic drugs",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    and NSAIDs have a well established role in the treatment of cancer pain when used as single agents [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4488/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. In addition, when used in combination with opioids, these agents may provide analgesia that is additive to the opioid regimen, permitting a reduction in the opioid dose, with a consequent lessening of opioid-related side effects.",
"   </p>",
"   <p>",
"    This topic review will cover the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    and NSAIDs in cancer pain management. The use of other adjuvant analgesics (coanalgesics) such as antidepressants, anticonvulsants, and glucocorticoids, an overview of assessment of cancer pain, a review of specific cancer pain syndromes, general principles of cancer pain management, the clinical use of opioid analgesics, an overview of risk management in patients treated with opioids, prevention and management of opioid side effects, and non-pharmacologic methods of cancer pain management are covered elsewhere. (See appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ACETAMINOPHEN",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     Acetaminophen",
"    </a>",
"    is an effective analgesic for patients with mild cancer pain [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4488/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Acetaminophen is also a component of a variety of combination opioid products. However, the evidence to support the benefit of acetaminophen in combination with a \"weak\" opioid (as in step 2 of the WHO analgesic ladder, (",
"    <a class=\"graphic graphic_figure graphicRef63298 \" href=\"UTD.htm?0/45/724\">",
"     figure 1",
"    </a>",
"    )) in patients with moderate to severe pain [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4488/abstract/2-7\">",
"     2-7",
"    </a>",
"    ], or for patients with severe pain in conjunction with high doses of a \"strong\" opioid, is surprisingly limited [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4488/abstract/8-12\">",
"     8-12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/7/30842?source=see_link&amp;anchor=H7#H7\">",
"     \"Cancer pain management with opioids: Optimizing analgesia\", section on 'Pure mu agonists conventionally used for moderate or severe pain in patients with limited to no opioid exposure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The analgesic mechanisms underlying the benefit of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    are poorly understood, but may involve inhibition of prostaglandin formation in the CNS, as well as other mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4488/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. In contrast to the NSAIDs, acetaminophen is not anti-inflammatory. The side effect profile is exceedingly good, but there is a relatively narrow therapeutic window and the main toxicity, hepatic injury, is a serious concern.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Hepatic toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conventionally, the maximum safe dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    has been considered to be 4",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    and the maximum safe dose in patients with significant comorbid liver disease or heavy alcohol consumption has been thought to be lower, eg, 2",
"    <span class=\"nowrap\">",
"     g/day.",
"    </span>",
"    In the United States, concerns about unintentional overdose have been rising, and government regulators have suggested that a maximum dose should be 2.6",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    (eight tablets per day of a formulation containing 325 mg per dose unit), and that patients with significant liver disease or heavy alcohol use should be considered to have a relative contraindication to this drug. In 2011, the FDA asked drug manufacturers to limit the strength of acetaminophen in prescription drug products to 325 mg per dosage unit [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4488/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     Acetaminophen",
"    </a>",
"    is a component of a variety of combination opioid products that are used for moderate to severe cancer pain. These combinations are a reasonable choice for opioid-na&iuml;ve patients with moderate cancer-related pain. However, the treatment of pain that worsens over time cannot be accomplished with these drugs because the amount of opioid that can be delivered is limited by the amount of acetaminophen in each dose; when the maximum dose of acetaminophen is reached, an alternative strategy for pain control is needed. The need to switch to a long-acting drug that obviates the need for repeated doses per day may be another reason to switch from one of these combinations if pain persists and is occurring during most of the day. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/7/30842?source=see_link&amp;anchor=H7#H7\">",
"     \"Cancer pain management with opioids: Optimizing analgesia\", section on 'Pure mu agonists conventionally used for moderate or severe pain in patients with limited to no opioid exposure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients who begin therapy with an opioid alone, a trial of fixed-schedule dosing with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    may be considered in those who have mild residual pain during opioid therapy. This approach is usually considered if the patient is very sensitive to opioid side effects. Patients who undertake this treatment must be educated to avoid unintentional overdose through the use of over the counter drug combinations that contain acetaminophen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     NONSTEROIDAL ANTIINFLAMMATORY AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The NSAIDS are a diverse group of drugs (",
"    <a class=\"graphic graphic_table graphicRef70067 \" href=\"UTD.htm?23/54/24431\">",
"     table 1",
"    </a>",
"    ) that presumably produce analgesia by inhibiting the enzyme cyclooxygenase (COX), and thereby reducing production of peripheral and central prostaglandins. There are two main isoforms of COX, a constitutive form (COX-1) that is active in tissues that require prostaglandins for physiologic function, and an inducible form (COX-2) that is produced in the setting of inflammation.",
"   </p>",
"   <p>",
"    Each of the NSAIDs inhibits both COX-1 and COX-2, but with varying selectively for the two isoforms. Drugs that are relatively more selective for COX-2 have analgesic and anti-inflammatory properties, but are relatively less likely to produce side effects related to COX-1 inhibition, such as gastrointestinal (GI) toxicity. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Side effects'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A number of drugs were specifically developed as relatively selective COX-2 inhibitors in order to reduce the risk of GI toxicity. Studies confirmed that these COX-2 selective drugs had lower rates of GI side effects, ulceration and bleeding, as long as low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    therapy was not undertaken concurrently. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13066?source=see_link&amp;anchor=H5#H5\">",
"     \"Overview of selective COX-2 inhibitors\", section on 'Effect of low-dose aspirin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cardiovascular toxicity has been identified in patients treated with any of the NSAIDs, and epidemiologic and other research has suggested that the prothrombotic effect that presumably causes this toxicity is produced by relatively excessive inhibition of the COX-2 enzyme. Mostly as a result of these concerns, two COX-2 selective NSAIDs were taken off the market in the United States, and others have not been approved. Subsequent research has confirmed that there is large drug-specific variation in the risk of cardiovascular toxicity among both the COX-2 selective drugs and the non-selective",
"    <span class=\"nowrap\">",
"     COX-1/COX-2",
"    </span>",
"    inhibitors.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"     Celecoxib",
"    </a>",
"    , currently the only available NSAID labeled a selective COX-2 inhibitor in the US, appears to have a far lower risk than other drugs in this class; similarly, some of the non-selective drugs, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    , appear to have relatively lower risk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39351?source=see_link\">",
"     \"COX-2 selective inhibitors: Adverse cardiovascular effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;NSAIDS are effective analgesics for cancer pain when used as single agents or in combination with opioids [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4488/abstract/2,3,12\">",
"     2,3,12",
"    </a>",
"    ]. There is more evidence to support additive analgesic benefit from the combination of an NSAID plus an opioid than there is with combinations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    plus an opioid. A 2005 meta-analysis included five trials comparing a step III opioid with or without an NSAID, four of which demonstrated greater efficacy for the combination as compared to an opioid alone [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4488/abstract/3\">",
"     3",
"    </a>",
"    ]. A later systematic review identified two other trials of a strong (step III, (",
"    <a class=\"graphic graphic_figure graphicRef63298 \" href=\"UTD.htm?0/45/724\">",
"     figure 1",
"    </a>",
"    )) opioid with or without an NSAID; five of the total seven studies showed an additive effect of NSAIDs when combined with opioids, either by improving analgesia (three studies) or reducing opioid dose (two studies) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4488/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon clinical observations, NSAIDs may be especially useful in patients with bone pain or pain that is related to grossly inflammatory lesions. They are relatively less useful in patients who have neuropathic pain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/9/39066?source=see_link&amp;anchor=H18#H18\">",
"     \"Cancer pain management: Adjuvant analgesics (coanalgesics)\", section on 'Drugs used for neuropathic pain'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the utility of NSAIDs for cancer pain is limited by side effects and a \"ceiling\" dose for analgesia, above which additional dose increments fail to produce more relief.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Side effects that may be associated with NSAIDs include the following (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17177?source=see_link\">",
"     \"Nonselective NSAIDs: Overview of adverse effects\"",
"    </a>",
"    ):",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Cardiovascular toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, cardiovascular toxicity (including angina and myocardial infarction, transient ischemic attack and stroke, and symptomatic peripheral vascular disease) was first recognized in patients treated with COX-2 selective drugs. However, it is likely that all NSAIDS, including the nonselective COX-1 and COX-2 inhibitors (the traditional NSAIDs), increase the risk of cardiovascular thrombosis. The US Food and Drug Administration has embraced this view, mandating a boxed warning attached to all these drugs. Although it is possible that the magnitude of risk is higher with the selective COX-2 inhibitors, this has not been conclusively established [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4488/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Among commonly used nonselective NSAIDs,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    appears to have the greatest relative cardiovascular safety [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4488/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24648?source=see_link\">",
"     \"Nonselective NSAIDs: Adverse cardiovascular effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The prothrombotic effects caused by NSAIDs presumably occur at the time dosing is initiated; however, the risk of adverse outcomes is cumulative over time. Furthermore, risk may increase further when there are concomitant adverse effects on blood pressure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/43/42674?source=see_link\">",
"     \"NSAIDs and acetaminophen: Effects on blood pressure and hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Gastrointestinal toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;NSAIDs produce both dyspepsia and gastroduodenal ulceration (peptic ulcer disease). The likelihood and severity are less with COX-2-selective drugs, at least over the short-term.",
"   </p>",
"   <p>",
"    Pretreatment risk stratification can be helpful to estimate the risk of NSAID-induced GI toxicity and guide management of these patients. The American College of Gastroenterology published guidelines for prevention of NSAID-induced ulcers in 2009 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4488/abstract/19\">",
"     19",
"    </a>",
"    ]. These guidelines risk stratify patients into high, moderate, or low risk for GI complications of NSAID use based upon the number of positive risk factors they have (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6745?source=see_link\">",
"     \"NSAIDs (including aspirin): Pathogenesis of gastroduodenal toxicity\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A history of an ulcer or GI hemorrhage, which increases risk four- to fivefold",
"     </li>",
"     <li>",
"      Age &gt;60, which increases risk five- to sixfold",
"     </li>",
"     <li>",
"      High (more than twice the customary) dosage of a NSAID, which increases risk 10-fold",
"     </li>",
"     <li>",
"      Concurrent use of glucocorticoids, which increases risk four- to fivefold",
"     </li>",
"     <li>",
"      Concurrent use of anticoagulants, which increases risk up to 15-fold (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=see_link&amp;anchor=H28#H28\">",
"       \"Therapeutic use of warfarin\", section on 'Bleeding'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    High-risk patients were defined as having a history of a previous complicated ulcer (especially recent) or &gt;2 other risk factors; the committee suggested avoiding NSAIDs in such patients. Low-risk patients have no risk factors. For moderate-risk patients, those with one to two risk factors, the committee recommended concomitant use of a gastroprotectant. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Improving the therapeutic ratio: choice of drug, dose and use of gastroprotectants'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The role of H. pylori infection in the development of peptic ulcer disease in patients treated with NSAIDs is uncertain. Nevertheless, some expert groups endorse testing for H. pylori for patients who are beginning NSAID therapy if they have a history of ulcer complications or a history of ulcer disease (non-bleeding), and treatment for those patients who are positive. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6745?source=see_link&amp;anchor=H10#H10\">",
"     \"NSAIDs (including aspirin): Pathogenesis of gastroduodenal toxicity\", section on 'Role of Helicobacter pylori infection'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6745?source=see_link\">",
"     \"NSAIDs (including aspirin): Pathogenesis of gastroduodenal toxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most NSAIDs interfere with platelet aggregation; two exceptions are the nonacetylated salicylates (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/43/42677?source=see_link\">",
"     choline magnesium trisalicylate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/14/5350?source=see_link\">",
"     salsalate",
"    </a>",
"    ) and the selective COX-2 inhibitors. Despite its short half-life,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    irreversibly inhibits platelet aggregation for the lifetime of the platelet (four to seven days); the inhibitory effect of other NSAIDs lasts about two days. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13066?source=see_link\">",
"     \"Overview of selective COX-2 inhibitors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17177?source=see_link&amp;anchor=H15#H15\">",
"     \"Nonselective NSAIDs: Overview of adverse effects\", section on 'Antiplatelet effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Nephrotoxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reversible renal insufficiency due to renal vasoconstriction, acute interstitial nephritis, and a predisposition to acute tubular necrosis in patients with low renal perfusion have been associated with NSAID use. Prolonged NSAID use also can cause chronic nephropathy, which may be irreversible. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24582?source=see_link\">",
"     \"NSAIDs: Acute kidney injury (acute renal failure) and nephrotic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Hepatotoxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatotoxicity can be seen with NSAIDs, even at recommended doses. The elevations in liver enzymes are generally mild and reversible with discontinuation of the NSAID. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17177?source=see_link&amp;anchor=H6#H6\">",
"     \"Nonselective NSAIDs: Overview of adverse effects\", section on 'Hepatic injury'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Indications and contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;A trial of a NSAID may be considered in any patient who has mild to moderate chronic cancer pain. However, the decision to offer treatment should consider the likelihood of benefit, the risk of adverse effects, and the cost and burden associated with prolonged treatment (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Side effects'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Based upon clinical observations, NSAIDs are especially useful in patients with bone pain or pain that is related to grossly inflammatory lesions, and relatively less useful in patients with neuropathic pain.",
"     </li>",
"     <li>",
"      Patients who are deemed at high risk for peptic ulcer disease or its complications as a result of advanced age, a history of peptic ulcer disease or prior NSAID gastroduodenopathy, advanced illness or bleeding diathesis, or concurrent corticosteroid use should be considered to have a relative contraindication to use of an NSAID. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Gastrointestinal toxicity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Given the likelihood that all NSAIDs have at least some prothrombotic effects, patients who have a strong history of cardiovascular disease or evidence of cancer-related hypercoagulability (eg, a history of venous thrombosis) also should be considered to have a relative contraindication to NSAID therapy. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Cardiovascular toxicity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All NSAIDs may cause serious nephrotoxicity, and preexisting renal disease (or strong predisposing factors, such as a diagnosis of multiple myeloma, or low perfusion states such as heart failure) represent contraindications to their use. NSAIDs should be prescribed with caution in patients with hypertension, renal insufficiency, or low renal perfusion states such as heart failure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Improving the therapeutic ratio: choice of drug, dose and use of gastroprotectants",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who have none of these contraindications and are reasonable candidates for NSAID therapy, it may be possible to reduce risk further through drug or dose selection and the use of concomitant therapy such as gastroprotectants.",
"   </p>",
"   <p>",
"    Although epidemiologic studies indicate the existence of substantial differences in risk across specific NSAIDs, there are few adequate comparative trials, and firm conclusions are not possible. Nevertheless, in general, GI risk correlates with antiinflammatory activity, and those NSAIDs whose analgesic and antiinflammatory doses are similar (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/25/9625?source=see_link\">",
"     piroxicam",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/62/35808?source=see_link\">",
"     ketorolac",
"    </a>",
"    ) pose a greater risk, and should probably be avoided. In addition to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"     celecoxib",
"    </a>",
"    , limited data suggest that some nonselective NSAIDs (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/18/39208?source=see_link\">",
"     nabumetone",
"    </a>",
"    , and the nonacetylated salicylates such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/43/42677?source=see_link\">",
"     choline magnesium trisalicylate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/14/5350?source=see_link\">",
"     salsalate",
"    </a>",
"    ) have a relatively lower risk of GI toxicity. Regardless of the drug selected, lower doses are associated with less risk than are higher doses.",
"   </p>",
"   <p>",
"    Thus, to minimize the risk of ulcer and related adverse effects, a trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"     celecoxib",
"    </a>",
"    could be considered, or if this is unavailable, ineffective or poorly tolerated,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    or one of the other relatively lower-risk NSAIDs. Taking the drug with food",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    antacids may also improve GI tolerance.",
"   </p>",
"   <p>",
"    Pharmacologic approaches to preventing gastroduodenal toxicity include the concurrent use of a gastroprotectant (eg, a proton pump inhibitor [PPI] such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    , or the prostaglandin analogue",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    ). A PPI is preferred over other preventive approaches because of their convenience and relatively good safety profile [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4488/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest coadministration of a PPI in patients who need an NSAID and who qualify as having moderate risk for gastrointestinal complications, as suggested in the AGA guidelines. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Gastrointestinal toxicity'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=see_link\">",
"     \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    At least some data suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    may have a lower risk of cardiovascular toxicity than other nonselective NSAIDs [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4488/abstract/17,21\">",
"     17,21",
"    </a>",
"    ]. However, there are conflicting data on this issue. Nevertheless, selection of naproxen is reasonable in a patient who is otherwise eligible for a trial of NSAID therapy if there is a relatively high concern about prothrombotic effects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24648?source=see_link\">",
"     \"Nonselective NSAIDs: Adverse cardiovascular effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because there is substantial variability in the response of individual patients to the various NSAIDs, the decision to try an NSAID may require several trials to identify the agent with the most favorable risk to benefit ratio. In addition to risk-related factors, there may be other important considerations as specific drugs are considered. For example, a past response to an NSAID may inform current drug selection. Pharmacokinetic considerations may also be important, in that an NSAID that can be given once daily (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/18/39208?source=see_link\">",
"     nabumetone",
"    </a>",
"    ) or twice daily (many options) is usually better for fixed schedule, open-ended dosing. Cost and availability considerations may also be relevant considerations.",
"   </p>",
"   <p>",
"    Regardless of the agent chosen, all patients receiving an NSAID should be evaluated periodically for occult fecal blood, changes in blood pressure, and effects on renal or hepatic function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/36/579?source=see_link\">",
"       \"Patient information: Managing pain when you have cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       Acetaminophen",
"      </a>",
"      and NSAIDs are non-opioid analgesics that are frequently used in the treatment of mild to moderate cancer-related pain. Analgesia may be additive to that of opioids, permitting a reduction in the opioid dose, with a consequent lessening of opioid-related side effects. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The use of combination products that include an opioid plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      (acetaminophen plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/0/35848?source=see_link\">",
"       codeine",
"      </a>",
"      , hydrocodone or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/34/10792?source=see_link\">",
"       oxycodone",
"      </a>",
"      ) is a reasonable alternative to low doses of a strong opioid alone for opioid-naive patients with moderate to severe cancer pain. However, hepatic injury from acetaminophen is a serious concern, and the amount of opioid that can be delivered is limited by the amount of acetaminophen in each unit dose. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Acetaminophen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A trial of an NSAID is reasonable for a patient with mild to moderate cancer-related pain and no contraindication to the use of NSAIDs. The likelihood of benefit and the risk of adverse effects must be considered. Relative contraindications to NSAID use include a history of peptic ulcer disease or prior NSAID gastroduodenopathy, a bleeding diathesis, or concurrent corticosteroid use, strong history of cardiovascular disease, evidence of cancer-related hypercoagulability, or preexisting renal disease. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Side effects'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Indications and contraindications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with cancer pain who otherwise appear to be candidates, we suggest a trial of an NSAID in the setting of bone pain or pain that has an inflammatory component (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Efficacy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Drugs of this class are less useful for neuropathic pain, and we suggest other therapeutic alternatives rather than NSAIDs in this setting (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Indications and contraindications'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/9/39066?source=see_link&amp;anchor=H18#H18\">",
"       \"Cancer pain management: Adjuvant analgesics (coanalgesics)\", section on 'Drugs used for neuropathic pain'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The choice of specific drug is empiric. NSAIDs that can be given once or twice daily are preferred (",
"      <a class=\"graphic graphic_table graphicRef70067 \" href=\"UTD.htm?23/54/24431\">",
"       table 1",
"      </a>",
"      ). If there is a desire to minimize GI toxicity, we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"       celecoxib",
"      </a>",
"      (if cardiovascular toxicity is not a concern) or one of the nonselective NSAIDs that have a relatively lower risk of GI toxicity (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"       ibuprofen",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"       naproxen",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/18/39208?source=see_link\">",
"       nabumetone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/43/42677?source=see_link\">",
"       choline magnesium trisalicylate",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/14/5350?source=see_link\">",
"       salsalate",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Improving the therapeutic ratio: choice of drug, dose and use of gastroprotectants'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If there is a desire to minimize the risk of cardiovascular toxicity,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"       naproxen",
"      </a>",
"      is a reasonable choice as it may have a lower risk of cardiovascular toxicity than other nonselective NSAIDs or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"       celecoxib",
"      </a>",
"      ; however, the risk of GI toxicity may be higher, at least higher than celecoxib.",
"     </li>",
"     <li>",
"      For all patients taking an NSAID, we suggest using the lowest dose possible, and taking each dose with food",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      antacids.",
"      <br/>",
"      <br/>",
"      We suggest coadministration of a proton pump inhibitor (PPI) in patients who require a NSAID and are at moderate risk for GI toxicity (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). This includes patients who: have a history of upper GI bleeding, are receiving a concomitant anticoagulation, a",
"      <strong>",
"       nd have",
"      </strong>",
"      more than one risk factor for complications, including age 60 or more, dyspepsia or reflux symptoms. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=see_link\">",
"       \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     World Health Organization. Cancer pain relief, 2nd, World Health Organization, Geneva 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4488/abstract/2\">",
"      Eisenberg E, Berkey CS, Carr DB, et al. Efficacy and safety of nonsteroidal antiinflammatory drugs for cancer pain: a meta-analysis. J Clin Oncol 1994; 12:2756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4488/abstract/3\">",
"      McNicol E, Strassels SA, Goudas L, et al. NSAIDS or paracetamol, alone or combined with opioids, for cancer pain. Cochrane Database Syst Rev 2005; :CD005180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4488/abstract/4\">",
"      de Craen AJ, Di Giulio G, Lampe-Schoenmaeckers JE, et al. Analgesic efficacy and safety of paracetamol-codeine combinations versus paracetamol alone: a systematic review. BMJ 1996; 313:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4488/abstract/5\">",
"      Curatolo M, Sveticic G. Drug combinations in pain treatment: a review of the published evidence and a method for finding the optimal combination. Best Pract Res Clin Anaesthesiol 2002; 16:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4488/abstract/6\">",
"      Chary S, Goughnour BR, Moulin DE, et al. The dose-response relationship of controlled-release codeine (Codeine Contin) in chronic cancer pain. J Pain Symptom Manage 1994; 9:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4488/abstract/7\">",
"      Sima L, Fang WX, Wu XM, Li F. Efficacy of oxycodone/paracetamol for patients with bone-cancer pain: a multicenter, randomized, double-blinded, placebo-controlled trial. J Clin Pharm Ther 2012; 37:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4488/abstract/8\">",
"      Axelsson B, Borup S. Is there an additive analgesic effect of paracetamol at step 3? A double-blind randomized controlled study. Palliat Med 2003; 17:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4488/abstract/9\">",
"      Stockler M, Vardy J, Pillai A, Warr D. Acetaminophen (paracetamol) improves pain and well-being in people with advanced cancer already receiving a strong opioid regimen: a randomized, double-blind, placebo-controlled cross-over trial. J Clin Oncol 2004; 22:3389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4488/abstract/10\">",
"      Israel FJ, Parker G, Charles M, Reymond L. Lack of benefit from paracetamol (acetaminophen) for palliative cancer patients requiring high-dose strong opioids: a randomized, double-blind, placebo-controlled, crossover trial. J Pain Symptom Manage 2010; 39:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4488/abstract/11\">",
"      Cubero DI, del Giglio A. Early switching from morphine to methadone is not improved by acetaminophen in the analgesia of oncologic patients: a prospective, randomized, double-blind, placebo-controlled study. Support Care Cancer 2010; 18:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4488/abstract/12\">",
"      Nabal M, Librada S, Redondo MJ, et al. The role of paracetamol and nonsteroidal anti-inflammatory drugs in addition to WHO Step III opioids in the control of pain in advanced cancer. A systematic review of the literature. Palliat Med 2012; 26:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4488/abstract/13\">",
"      Anderson BJ. Paracetamol (Acetaminophen): mechanisms of action. Paediatr Anaesth 2008; 18:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4488/abstract/14\">",
"      Pickering G, Loriot MA, Libert F, et al. Analgesic effect of acetaminophen in humans: first evidence of a central serotonergic mechanism. Clin Pharmacol Ther 2006; 79:371.",
"     </a>",
"    </li>",
"    <li>",
"     FDA Drug Safety Communication available online at file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm239955.htm (Accessed on January 14, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4488/abstract/16\">",
"      Hinz B, Renner B, Brune K. Drug insight: cyclo-oxygenase-2 inhibitors--a critical appraisal. Nat Clin Pract Rheumatol 2007; 3:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4488/abstract/17\">",
"      Farkouh ME, Greenberg BP. An evidence-based review of the cardiovascular risks of nonsteroidal anti-inflammatory drugs. Am J Cardiol 2009; 103:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4488/abstract/18\">",
"      Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011; 342:c7086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4488/abstract/19\">",
"      Lanza FL, Chan FK, Quigley EM, Practice Parameters Committee of the American College of Gastroenterology. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 2009; 104:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4488/abstract/20\">",
"      Lazzaroni M, Porro GB. Management of NSAID-induced gastrointestinal toxicity: focus on proton pump inhibitors. Drugs 2009; 69:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4488/abstract/21\">",
"      Scheiman JM. Prevention of NSAID-Induced Ulcers. Curr Treat Options Gastroenterol 2008; 11:125.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2798 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-122.72.80.101-1C61674EA5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_24_4488=[""].join("\n");
var outline_f4_24_4488=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ACETAMINOPHEN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Hepatic toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      NONSTEROIDAL ANTIINFLAMMATORY AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Side effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Cardiovascular toxicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Gastrointestinal toxicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Bleeding",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Hepatotoxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Indications and contraindications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Improving the therapeutic ratio: choice of drug, dose and use of gastroprotectants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PALC/2798\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PALC/2798|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/45/724\" title=\"figure 1\">",
"      WHO analgesic ladder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PALC/2798|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/54/24431\" title=\"table 1\">",
"      Nonopioid analgesic and NSAID table",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39351?source=related_link\">",
"      COX-2 selective inhibitors: Adverse cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/7/30842?source=related_link\">",
"      Cancer pain management with opioids: Optimizing analgesia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/9/39066?source=related_link\">",
"      Cancer pain management: Adjuvant analgesics (coanalgesics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43704?source=related_link\">",
"      Cancer pain management: General principles and risk management for patients receiving opioids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6745?source=related_link\">",
"      NSAIDs (including aspirin): Pathogenesis of gastroduodenal toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=related_link\">",
"      NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/43/42674?source=related_link\">",
"      NSAIDs and acetaminophen: Effects on blood pressure and hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24582?source=related_link\">",
"      NSAIDs: Acute kidney injury (acute renal failure) and nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24648?source=related_link\">",
"      Nonselective NSAIDs: Adverse cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17177?source=related_link\">",
"      Nonselective NSAIDs: Overview of adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13066?source=related_link\">",
"      Overview of selective COX-2 inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/36/579?source=related_link\">",
"      Patient information: Managing pain when you have cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=related_link\">",
"      Therapeutic use of warfarin",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_24_4489="Epidemiology of and risk factors for gallstones";
var content_f4_24_4489=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology of and risk factors for gallstones",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/24/4489/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/24/4489/contributors\">",
"     Nezam H Afdhal, MD, FRCPI",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/24/4489/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/24/4489/contributors\">",
"     Sanjiv Chopra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/24/4489/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/24/4489/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/24/4489/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gallstone disease is one of the most common and costly of all digestive diseases. The third National Health and Nutrition Examination Survey estimated that 6.3 million men and 14.2 million women aged 20 to 74 in the United States had gallbladder disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4489/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Over the past two decades, a great deal has been learned about the epidemiology of and risk factors for gallstones (",
"    <a class=\"graphic graphic_table graphicRef81139 \" href=\"UTD.htm?7/47/7932\">",
"     table 1",
"    </a>",
"    ). Ultrasonography has played a major role in this process, providing a rapid, risk-free method of screening large populations. Prior to the availability of ultrasound, most studies relied on highly selective autopsy data and limited oral cholecystography.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidemiologic data are available from a number of large European and American populations (",
"    <a class=\"graphic graphic_table graphicRef57092 \" href=\"UTD.htm?0/50/814\">",
"     table 2",
"    </a>",
"    ). These studies have revealed a marked variation in overall gallstone prevalence between different ethnic populations. As a general rule, there appears to be higher rates of cholelithiasis in western Caucasian, Hispanic, and Native American populations and lower rates in eastern European, African American, and Japanese populations [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4489/abstract/2-18\">",
"     2-18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the United States, the age standardized prevalence of gallbladder disease was estimated based upon a sample of more than 14,000 persons aged 20 to 74 in whom gallbladder disease was detected by the presence of gallstones or cholecystectomy on ultrasonography [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4489/abstract/1\">",
"     1",
"    </a>",
"    ]. The following prevalence rates were observed:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      8.6 and 16.6 percent among non-Hispanic white men and women, respectively",
"     </li>",
"     <li>",
"      8.9 and 26.7 percent among Mexican American men and women, respectively",
"     </li>",
"     <li>",
"      5.3 percent and 13.9 percent among non-Hispanic black men and women, respectively",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In other studies, Native Americans had the highest prevalence of cholelithiasis in North America. As an example, 73 percent of female Pima Indians over the age of 25 years have gallstones [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4489/abstract/8\">",
"     8",
"    </a>",
"    ]. Similar high rates have been found in multiple other Native American populations [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4489/abstract/9,10,19\">",
"     9,10,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As illustrated above, African Americans appear to have the lowest prevalence of cholelithiasis. Autopsy based studies performed in the 1950s found that African Americans had one-half to one-quarter the risk of cholelithiasis compared to Caucasian Americans [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4489/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]; later reports have shown a 40 percent lower risk of hospitalization for gallstone related disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4489/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Large ultrasound based studies from Europe have characterized both gallstone prevalence and incidence. As an example, the Multicenter Italian Study of Cholelithiasis (MICOL) examined nearly 33,000 subjects aged 30 to 69 years in 18 cohorts in 10 Italian regions [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4489/abstract/13\">",
"     13",
"    </a>",
"    ]. The overall rate of gallstone disease was 18.8 percent in women and 9.5 percent in men [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4489/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar results were noted in the Sirmione study in which an overall prevalence rate of 11 percent in 1930 Italian subjects between the ages of 18 and 65 years was noted [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4489/abstract/14\">",
"     14",
"    </a>",
"    ]. Ultrasound examinations were repeated on the same patients at five-year intervals. The 10-year cumulative incidence of new gallstones was 4.6 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the variability of gallstones in different ethnic populations, a number of other risk factors for this condition have been identified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Age",
"    </span>",
"    &nbsp;&mdash;&nbsp;Age is a major risk factor for the gallstones. Gallstones are exceedingly rare in children except in the presence of hemolytic states; in addition, less than 5 percent of all cholecystectomies are performed in children. Age 40 appears to represent the cut-off between relatively low and high rates of cholecystectomies. This observation was validated in the Sirmione study in which the incidence between the ages of 40 and 69 years was four times higher than that in younger subjects. Among the 135 patients with gallstones, only one was between the ages of 18 and 21 years [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4489/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Sex",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, a higher prevalence of gallstones has been observed in women in all age groups [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4489/abstract/7,8,13\">",
"     7,8,13",
"    </a>",
"    ]. The difference between women and men is particularly striking in young adults. The GREPCO study found a female-to-male ratio of 2.9 between the ages of 30 to 39 years; the ratio narrowed to 1.6 between the ages of 40 to 49 years and 1.2 between the ages of 50 to 59 years [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4489/abstract/20\">",
"     20",
"    </a>",
"    ]. The higher rates in young women is almost certainly a result of pregnancy and sex steroids.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy is a major risk factor for the development of cholesterol gallstones. The risk is related to both the frequency and number of pregnancies. In one report, for example, the prevalence of gallstones increased from 1.3 percent in nulliparous females to 12.2 percent in multiparous females [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4489/abstract/21\">",
"     21",
"    </a>",
"    ]. Another study recruited 272 women in the first trimester of pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4489/abstract/22\">",
"     22",
"    </a>",
"    ]. The incidence of new biliary sludge and gallstones was 31 and 2 percent, respectively.",
"   </p>",
"   <p>",
"    Sex hormones induce a variety of physiologic changes in the biliary system, which ultimately cause bile to become supersaturated with cholesterol, thereby promoting gallstone formation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Supersaturation occurs as a result of an estrogen induced increase in cholesterol secretion and a progesterone induced reduction in bile acid secretion [",
"      <a class=\"abstract\" href=\"UTD.htm?4/24/4489/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Pregnancy induces a qualitative change in bile acid synthesis characterized by relative overproduction of hydrophobic bile acids such as chenodeoxycholate, thereby reducing the ability of bile to solubilize cholesterol [",
"      <a class=\"abstract\" href=\"UTD.htm?4/24/4489/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Progesterone induced slowing of gallbladder emptying further promotes the formation of stones by causing bile stasis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These changes normalize one to two months following delivery. In the postpartum period, gallbladder sludge resolves in 61 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4489/abstract/22\">",
"     22",
"    </a>",
"    ] and approximately 30 percent of stones smaller than 10 mm disappear due at least in part to unsaturation of bile [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4489/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Oral contraceptives and estrogen replacement therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most studies have shown that estrogen therapy is associated with higher rates of gallstones [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4489/abstract/25-28\">",
"     25-28",
"    </a>",
"    ]. The following associations have been noted in different reports:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A secondary analysis of data from the Women's Health Initiative (consisting of two randomized placebo-controlled trials comparing estrogen or estrogen plus progestin in postmenopausal women with and without a hysterectomy, respectively) found a significantly increased risk of biliary tract disease among women using estrogen therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?4/24/4489/abstract/29\">",
"       29",
"      </a>",
"      ]. Both trials showed a greater risk of any gallbladder disease or surgery in the groups randomized to estrogen (hazard ratios [HR] of 1.67 and 1.59 in the estrogen alone and estrogen plus progestin studies, respectively). Women receiving estrogen were more likely to experience an episode of cholecystitis (HR of 1.80 and 1.54, respectively) and were more likely to undergo cholecystectomy (HR of 1.93 and 1.67, respectively).",
"     </li>",
"     <li>",
"      In a prospective cohort study that included 1,001,391 women with 6,102,811 person-years of follow-up, 19,889 women (2 percent) had a first admission for gallbladder disease [",
"      <a class=\"abstract\" href=\"UTD.htm?4/24/4489/abstract/30\">",
"       30",
"      </a>",
"      ]. Gallbladder disease was defined as a primary diagnosis of cholelithiasis or cholecystitis or a cholecystectomy. Compared with women who had never used hormone replacement therapy, current and past users had an increased risk of gallbladder disease (relative risk [RR] 1.64). Among current users of hormone replacement therapy, compared with never-users, the risk of gallbladder disease was lower with transdermal therapy than with oral therapy (RR 1.17 versus 1.68).",
"     </li>",
"     <li>",
"      In the Nurses' Health Study of almost 55,000 postmenopausal women, those currently using postmenopausal hormones were at an increased risk of cholecystectomy (RR 2.1) compared to never-users [",
"      <a class=\"abstract\" href=\"UTD.htm?4/24/4489/abstract/26\">",
"       26",
"      </a>",
"      ]. For current users, the risk of cholecystectomy increased with increasing duration of hormone use and higher doses of estrogen. The risk for past hormone users decreased substantially in women who had discontinued use within the preceding one to three years (RR 1.6), a small but significant risk persisted for women who had stopped taking ERT five or more years previously (RR 1.3).",
"     </li>",
"     <li>",
"      Men receiving estrogen therapy had an increased rate of gallstones compared to controls. In one study of men who had had a myocardial infarction, treatment with estrogen or clofibrate was associated with more than a twofold increase in risk of gallbladder disease compared to those receiving placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?4/24/4489/abstract/31\">",
"       31",
"      </a>",
"      ]. In another report of men with prostate cancer, new gallstones detected by ultrasonography developed at one year in 5 of 28 men treated with estrogen compared to none of 26 who underwent orchiectomy [",
"      <a class=\"abstract\" href=\"UTD.htm?4/24/4489/abstract/27\">",
"       27",
"      </a>",
"      ]. Estrogen treated men had a 40 percent increase in biliary cholesterol excretion compared to age matched controls.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Oral contraceptive use also appears to cause a slight increase in the risk of gallstone formation. Women under the age of 40 and those taking high-dose estrogen (&gt;50 mcg) preparations have the greatest added risk [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4489/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. It has been suggested that oral contraceptive has only a transient effect on gallstone formation. In support of this hypothesis, a case control study found a slightly higher incidence of gallstones shortly after starting oral contraceptives, an effect which disappeared after 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4489/abstract/34\">",
"     34",
"    </a>",
"    ]. A similar relationship was noted in a meta-analysis of controlled epidemiologic studies [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4489/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Family history and genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Family history studies suggest that genetics has a significant role in the development of gallstones. Investigators performed oral cholecystography in 171 first-degree relatives of patients with gallstones and 200 age matched controls [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4489/abstract/36\">",
"     36",
"    </a>",
"    ]. Gallstones occurred more than twice as often in the family group: 20.5 versus 9 percent. A more recent study evaluated 330 first-degree relatives of 105 patients with gallstones using ultrasonography; cholelithiasis was found in 15.5 percent compared to only 3.6 percent of matched controls [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4489/abstract/37\">",
"     37",
"    </a>",
"    ]. The risk was greater in female relatives in both of these studies.",
"   </p>",
"   <p>",
"    The great variation in gallstone rates amongst different ethnic groups described above could be due to genetic as well as dietary and cultural habits. A dramatic example occurs in Pima Indians who have exceptionally high rates of cholesterol gallstones: 73 percent in women over the age of 25 years [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4489/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Obesity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obesity (defined as weight greater than 120 percent of ideal body weight) is a well established risk factor for the development of cholesterol gallstones, presumably due to enhanced cholesterol synthesis and secretion (",
"    <a class=\"graphic graphic_figure graphicRef74965 \" href=\"UTD.htm?39/40/40589\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4489/abstract/38-41\">",
"     38-41",
"    </a>",
"    ]. The risk is particularly high in women [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4489/abstract/20,42,43\">",
"     20,42,43",
"    </a>",
"    ], in those with morbid obesity [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4489/abstract/41,44\">",
"     41,44",
"    </a>",
"    ], and in younger age groups in which a threefold increase in risk has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4489/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It has also been suggested that the incidence of gallbladder disease in morbidly obese subjects may be higher than expected from ultrasonography or oral cholecystography. In one report, 62 morbidly obese patients underwent prophylactic cholecystectomy at the time of a gastric exclusion procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4489/abstract/44\">",
"     44",
"    </a>",
"    ]. Among the 47 who had normal imaging studies, 40 had abnormal histologic findings in the gallbladder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Rapid weight loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rapid weight loss is also a risk factor for gallstone formation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/58/41898?source=see_link\">",
"     \"Complications of bariatric surgery\"",
"    </a>",
"    .) High rates of gallstone formation have also been associated with very low calorie diets [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4489/abstract/45-47\">",
"     45-47",
"    </a>",
"    ]. Gallstones which form in association with rapid weight loss appear to be more common in Caucasians and women.",
"   </p>",
"   <p>",
"    The mechanism by which this occurs is incompletely understood. One report evaluated changes in gallbladder bile during periods of weight loss [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4489/abstract/48\">",
"     48",
"    </a>",
"    ]. Bile mucin content increased 18-fold and bile calcium concentration rose 40 percent. These factors may promote cholesterol nucleation and stone formation.",
"   </p>",
"   <p>",
"    In contrast to the general population in which the great majority of gallstones are asymptomatic, persons with weight loss related cholelithiasis are more likely to be symptomatic. In one series, for example, 28 percent of patients required urgent cholecystectomy within three months after a gastric exclusion procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4489/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prophylaxis with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12373?source=see_link\">",
"     ursodeoxycholic acid",
"    </a>",
"    (UDCA) has been shown to be effective at reducing the risk of stone formation during rapid weight loss. In one trial of 1004 patients treated with a very low calorie diet, ultrasonography was performed at baseline and 8 and 16 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4489/abstract/47\">",
"     47",
"    </a>",
"    ]. The incidence of gallstones was 28 percent in the placebo group compared to 8, 3, and 2 percent of those treated with 300, 600, and 1200",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of UDCA, respectively.",
"   </p>",
"   <p>",
"    In another controlled trial, 68 obese subjects were randomized to UDCA (1200",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , or placebo at the time of entry into a 520",
"    <span class=\"nowrap\">",
"     kcal/day",
"    </span>",
"    diet program [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4489/abstract/46\">",
"     46",
"    </a>",
"    ]. The patients were treated for up to 16 weeks and were reevaluated at four and three weeks after treatment. None of the patients treated with UDCA developed gallstones or cholesterol crystals in the bile compared to five and six patients, respectively, in the placebo group (p&lt;0.001). The bile saturation index fell by about 18 percent with UDCA compared to a 20 percent elevation in the patients receiving placebo.",
"   </p>",
"   <p>",
"    Based upon these observations, we recommend that obese patients should be started on UDCA, 600 mg at night, during very low calorie diets or after weight reduction surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Diabetes mellitus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diabetes mellitus appears to be associated with an increased risk of gallstones. As an example, a case control study compared 336 patients who had gallstones or had undergone cholecystectomy to 336 controls [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4489/abstract/49\">",
"     49",
"    </a>",
"    ]. Diabetes was more prevalent in the patients with gallbladder disease (11.6 versus 4.8 percent). In another case control study, an increased prevalence of gallstones in diabetes could only be demonstrated in women (42 versus 26 percent in nondiabetic women) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4489/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    How diabetes predisposes to gallstones is not well understood. Hepatic insulin resistance appears to be important [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4489/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. Other contributing factors may be hypertriglyceridemia and autonomic neuropathy leading to biliary stasis due to gallbladder hypomotility [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4489/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Serum lipids",
"    </span>",
"    &nbsp;&mdash;&nbsp;The precise role of serum lipids on gallstone formation is not known. Gallstones appear to be positively associated with apolipoprotein E4 phenotype and elevated serum triglycerides [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4489/abstract/54-56\">",
"     54-56",
"    </a>",
"    ]. In contrast, a negative association exists between gallstones and high density lipoprotein. There is no conclusive evidence linking elevated serum cholesterol and gallstones [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4489/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Cirrhosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cirrhosis is a major risk factor for gallstones. The increased risk was illustrated in a combined cross-sectional and longitudinal study that included 1010 patients with cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4489/abstract/58\">",
"     58",
"    </a>",
"    ]. The overall prevalence of gallstones was 29.5 percent. During an average follow-up of 50 months, 141 of 618 patients (23 percent) developed gallstones (which is approximately 10 times higher than would be expected in a general population). Multivariate analysis demonstrated that the risk was increased in patients with Child classes B and C cirrhosis (regardless of the cause), and in patients with a high body mass index. The increased risk of gallstone formation in these patients may be due to several factors, including reduced hepatic synthesis and transport of bile salts and nonconjugated bilirubin, high estrogen levels, and impaired gallbladder contraction in response to a meal [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4489/abstract/59-61\">",
"     59-61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Gallbladder stasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conditions that result in bile stasis are associated with a higher prevalence of gallstones. In the normal state, the gallbladder avidly absorbs water from bile. Thus, if bile remains within the gallbladder for a prolonged period, it can become overly concentrated with cholesterol, thereby promoting stone formation. Common examples of this mechanism include spinal cord injuries, prolonged fasting and the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"     total parenteral nutrition",
"    </a>",
"    (both of which prevent the normal enteral stimulation of gallbladder activity), and excess somatostatin [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4489/abstract/62-67\">",
"     62-67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gallstones are a frequent complication of prolonged",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"       total parenteral nutrition",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?4/24/4489/abstract/63,64\">",
"       63,64",
"      </a>",
"      ]. As an example, one study of 84 patients with severe short bowel syndrome treated with total parenteral nutrition found asymptomatic gallstones in 44 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?4/24/4489/abstract/64\">",
"       64",
"      </a>",
"      ]. Two factors are thought to contribute: biliary stasis due to lack of enteral stimulation; and, in patients with ileal resection, interruption of the enterohepatic circulation of bile acids results in a reduction in hepatic bile acid secretion and an altered composition of hepatic bile which becomes supersaturated with respect to cholesterol.",
"     </li>",
"     <li>",
"      Somatostatin, probably via reduced cholecystokinin release, is a potent inhibitor of gallbladder emptying. Thus, stasis-induced gallstones may be seen in patients with a somatostatinoma or the long-term administration of the somatostatin analogue",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"       octreotide",
"      </a>",
"      in the treatment of acromegaly and other disorders [",
"      <a class=\"abstract\" href=\"UTD.htm?4/24/4489/abstract/65-67\">",
"       65-67",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/34/3623?source=see_link\">",
"       \"Somatostatinoma\"",
"      </a>",
"      .) Up to 25 percent of patients develop asymptomatic cholesterol gallstones or sludge during the first 18 months of therapy with octreotide [",
"      <a class=\"abstract\" href=\"UTD.htm?4/24/4489/abstract/66,67\">",
"       66,67",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Other drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to estrogen, oral contraceptives, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    , two other drugs can promote the formation of gallstones: clofibrate and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clofibrate, a now rarely used cholesterol lowering agent, is strongly associated with gallstones. Clofibrate and other fibrates (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/40/12933?source=see_link\">",
"       bezafibrate",
"      </a>",
"      ) reduce bile acid secretion by inhibiting the rate limiting enzyme in bile acid synthesis, cholesterol 7-alpha-hydroxylase; this results in cholesterol supersaturated bile and stone precipitation [",
"      <a class=\"abstract\" href=\"UTD.htm?4/24/4489/abstract/68\">",
"       68",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       Ceftriaxone",
"      </a>",
"      is a major cause of biliary sludge formation in hospitalized patients. Biliary excretion accounts for up to 40 percent of ceftriaxone elimination and drug concentrations in bile can reach 200 times that of the serum [",
"      <a class=\"abstract\" href=\"UTD.htm?4/24/4489/abstract/69,70\">",
"       69,70",
"      </a>",
"      ]. When supersaturated, ceftriaxone complexes with calcium and precipitates out of bile. This process is probably potentiated in intensive care unit patients who are not fed enterally and have bile stasis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Decreased physical activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical activity is associated with a decreased risk of symptomatic cholelithiasis. This was illustrated in the Physicians' Health Study, a prospective cohort study of over 45,000 men, in which 828 subjects developed symptomatic gallstones during eight years of follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4489/abstract/71\">",
"     71",
"    </a>",
"    ]. The men in the lowest quintile of physical activity had a relative risk of 1.72 between the ages of 40 and 64 and 1.33 above age 64 compared to those in the highest quintile. It was estimated that 34 percent of cases of symptomatic gallstones in men could be prevented by 30 minutes of endurance-type training five times per week.",
"   </p>",
"   <p>",
"    The Nurses' Health Study also demonstrated the benefit of physical activity for the prevention of symptomatic cholelithiasis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4489/abstract/72\">",
"     72",
"    </a>",
"    ]. The study included 60,290 women between the ages of 40 to 65 who were followed for 10 years during which 3257 underwent cholecystectomy. On multivariate analysis, the relative risk for women in the highest compared to the lowest quintile of physical activity was 0.69. In contrast, women who had a sedentary lifestyle were at increased risk of cholecystectomy (relative risk 1.42).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Crohn's disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of gallstones is increased in patients with Crohn's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4489/abstract/73-76\">",
"     73-76",
"    </a>",
"    ]. In a population based study in Sweden, for example, gallstones were detected in 26 percent of patients with Crohn's disease, which was approximately twice as frequent as the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4489/abstract/73\">",
"     73",
"    </a>",
"    ]. Gallstones in patients with ileal Crohn's disease (or those who have undergone ileal resection) are frequently pigment based, reflecting an increased concentration of bilirubin conjugates, unconjugated bilirubin, and total calcium in the gallbladder bile due perhaps to altered enterohepatic cycling of bilirubin [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4489/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Hemolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disorders associated with hemolysis increase the risk of pigmented gallstones. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/3/18489?source=see_link\">",
"     \"Approach to the diagnosis of hemolytic anemia in the adult\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     PROTECTIVE FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of statins, as well as a number of dietary factors, may protect against gallstone disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Statins",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of statins has been associated with a decreased risk of gallstone disease. A case-control study compared 27,035 patients with gallstone disease requiring cholecystectomy with 106,531 matched controls [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4489/abstract/77\">",
"     77",
"    </a>",
"    ]. Long-term statin use (&gt;20 prescriptions filled) was associated with a decreased risk of gallstone disease requiring cholecystectomy (adjusted OR 0.64). The protective effect of statins started to be seen after approximately 1 to 1.5 years of statin use.",
"   </p>",
"   <p>",
"    Similar results were observed in a population study from Denmark with 32,494 patients with gallstone disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4489/abstract/78\">",
"     78",
"    </a>",
"    ]. The cases were matched with 324,925 controls. Among current statin users who had filled at least 20 prescriptions, the odds ratio of having gallstone disease was 0.76 compared with nonusers. In prior users who had filled at least 20 prescriptions, the odds ratio was 0.79.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Ascorbic acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;The observation that deficiency of ascorbic acid (vitamin C) is associated with the development of gallstones in guinea pigs prompted investigation of the relationship between ascorbic acid levels and gallstones in humans. One study included 7042 women and 6088 men who were enrolled in the Third National Health and Nutrition Examination Survey. In that survey, a history of clinical or asymptomatic gallstones was correlated with serum ascorbic acid levels [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4489/abstract/79\">",
"     79",
"    </a>",
"    ]. Among women, each standard deviation increase in serum ascorbic acid levels (27",
"    <span class=\"nowrap\">",
"     &micro;mol/L)",
"    </span>",
"    was associated with a 13 percent lower prevalence of clinical gallbladder disease. For unclear reasons, the relationship did not hold true in men. The benefit of ascorbic acid may be related to its effects on cholesterol catabolism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Coffee",
"    </span>",
"    &nbsp;&mdash;&nbsp;Moderate coffee consumption was associated with a reduced risk of symptomatic gallstone disease in a cohort study involving 46,000 male health professionals who were followed for up to 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4489/abstract/80\">",
"     80",
"    </a>",
"    ]. Subjects who consistently drank two to three cups of regular coffee per day were approximately 40 percent less likely to develop symptomatic gallstones during follow-up. The benefit was even greater in those who drank four or more cups per day (relative risk 0.55). In contrast, decaffeinated coffee was not protective. A similar benefit from regular coffee was noted in a cohort study involving 81,000 women [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4489/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanism of benefit is not precisely known. Coffee has several effects on hepatobiliary processes involved in cholesterol gallstone formation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Vegetable protein",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Nurses' Health Study identified increased consumption of vegetable protein in the context of an energy-balanced diet as a protective factor for cholecystectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4489/abstract/82\">",
"     82",
"    </a>",
"    ]. Comparing the highest with the lowest quintiles of intake, the risk was reduced by about 20 percent (relative risk 0.79, 95% CI 0.71 to 0.88), with a significant dose-response relationship.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Poly- and monounsaturated fats",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mono- and polyunsaturated fats inhibit cholesterol gallstone formation in animals. Whether diets rich in these fats reduce the risk of gallstone disease was evaluated in the Health Professionals Follow-up Study, a large cohort study of male health professionals begun in 1986 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4489/abstract/83\">",
"     83",
"    </a>",
"    ]. After 14 years of follow-up, the relative risk in those in the highest compared with the lowest quintile of polyunsaturated and monounsaturated fat consumption were 0.84 (95% CI 0.73-0.96) and 0.83 (95% CI 0.70-1.00), respectively. This suggests that a high intake of polyunsaturated and monounsaturated fats in the context of an energy-balanced diet is associated with a reduced risk of gallstone disease in men.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?8/29/8658?source=see_link\">",
"       \"Patient information: Gallstones (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/56/1923?source=see_link\">",
"       \"Patient information: Gallbladder removal (cholecystectomy) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?7/21/7507?source=see_link\">",
"       \"Patient information: Gallstones (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Epidemiologic data are available from a number of large European and American populations (",
"      <a class=\"graphic graphic_table graphicRef57092 \" href=\"UTD.htm?0/50/814\">",
"       table 2",
"      </a>",
"      ). These studies have revealed a marked variation in overall gallstone prevalence between different ethnic populations. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In addition to the variability of gallstones in different ethnic populations, a number of other risk factors for this condition have been identified (",
"      <a class=\"graphic graphic_table graphicRef81139 \" href=\"UTD.htm?7/47/7932\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A number of dietary factors have been suggested as being protective against gallstone disease. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Protective factors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4489/abstract/1\">",
"      Everhart JE, Khare M, Hill M, Maurer KR. Prevalence and ethnic differences in gallbladder disease in the United States. Gastroenterology 1999; 117:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4489/abstract/2\">",
"      TORVIK A, HOIVIK B. Gallstones in an autopsy series. Incidence, complications, and correlations with carcinoma of the gallbladder. Acta Chir Scand 1960; 120:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4489/abstract/3\">",
"      Zahor A, Sternby NH, Kagan A, et al. Frequency of cholelithiasis in Prague and Malm&ouml;. An autopsy study. Scand J Gastroenterol 1974; 9:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4489/abstract/4\">",
"      Brett M, Barker DJ. The world distribution of gallstones. Int J Epidemiol 1976; 5:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4489/abstract/5\">",
"      Lindstr&ouml;m CG. Frequency of gallstone disease in a well-defined Swedish population. A prospective necropsy study in Malm&ouml;. Scand J Gastroenterol 1977; 12:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4489/abstract/6\">",
"      Heaton KW, Braddon FE, Mountford RA, et al. Symptomatic and silent gall stones in the community. Gut 1991; 32:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4489/abstract/7\">",
"      Maurer KR, Everhart JE, Ezzati TM, et al. Prevalence of gallstone disease in Hispanic populations in the United States. Gastroenterology 1989; 96:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4489/abstract/8\">",
"      Sampliner RE, Bennett PH, Comess LJ, et al. Gallbladder disease in pima indians. Demonstration of high prevalence and early onset by cholecystography. N Engl J Med 1970; 283:1358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4489/abstract/9\">",
"      Thistle JL, Eckhart KL Jr, Nensel RE, et al. Prevalence of gallbladder disease among Chippewa Indians. Mayo Clin Proc 1971; 46:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4489/abstract/10\">",
"      Williams CN, Johnston JL, Weldon KL. Prevalence of gallstones and gallbladder disease in Canadian Micmac Indian women. Can Med Assoc J 1977; 117:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4489/abstract/11\">",
"      WILBUR RS, BOLT RJ. Incidence of gall bladder disease in normal men. Gastroenterology 1959; 36:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4489/abstract/12\">",
"      Williams CN, Johnston JL. Prevalence of gallstones and risk factors in Caucasian women in a rural Canadian community. Can Med Assoc J 1980; 122:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4489/abstract/13\">",
"      Attili AF, Carulli N, Roda E, et al. Epidemiology of gallstone disease in Italy: prevalence data of the Multicenter Italian Study on Cholelithiasis (M.I.COL.). Am J Epidemiol 1995; 141:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4489/abstract/14\">",
"      Barbara L, Sama C, Morselli-Labate AM, et al. A ten year incidence of gallstone disease: The Sirmione study. J Hepatol 1993; 18(Suppl 1):S43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4489/abstract/15\">",
"      CUNNINGHAM JA, HARDENBERGH FE. Comparative incidence of choletithiasis in the Negro and white races; a study of 6185 autopsies. AMA Arch Intern Med 1956; 97:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4489/abstract/16\">",
"      NEWMAN HF, NORTHUP JD. The autopsy incidence of gallstones. Surg Gynecol Obstet 1959; 109:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4489/abstract/17\">",
"      Sichieri R, Everhart JE, Roth HP. Low incidence of hospitalization with gallbladder disease among blacks in the United States. Am J Epidemiol 1990; 131:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4489/abstract/18\">",
"      Nomura H, Kashiwagi S, Hayashi J, et al. Prevalence of gallstone disease in a general population of Okinawa, Japan. Am J Epidemiol 1988; 128:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4489/abstract/19\">",
"      Everhart JE, Yeh F, Lee ET, et al. Prevalence of gallbladder disease in American Indian populations: findings from the Strong Heart Study. Hepatology 2002; 35:1507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4489/abstract/20\">",
"      The epidemiology of gallstone disease in Rome, Italy. Part I. Prevalence data in men. The Rome Group for Epidemiology and Prevention of Cholelithiasis (GREPCO). Hepatology 1988; 8:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4489/abstract/21\">",
"      Valdivieso V, Covarrubias C, Siegel F, Cruz F. Pregnancy and cholelithiasis: pathogenesis and natural course of gallstones diagnosed in early puerperium. Hepatology 1993; 17:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4489/abstract/22\">",
"      Maringhini A, Ciambra M, Baccelliere P, et al. Biliary sludge and gallstones in pregnancy: incidence, risk factors, and natural history. Ann Intern Med 1993; 119:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4489/abstract/23\">",
"      Everson GT. Pregnancy and gallstones. Hepatology 1993; 17:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4489/abstract/24\">",
"      Kern F Jr, Everson GT, DeMark B, et al. Biliary lipids, bile acids, and gallbladder function in the human female. Effects of pregnancy and the ovulatory cycle. J Clin Invest 1981; 68:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4489/abstract/25\">",
"      Honor&eacute; LH. Increased incidence of symptomatic cholesterol cholelithiasis in perimenopausal women receiving estrogen replacement therapy: a retrospective study. J Reprod Med 1980; 25:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4489/abstract/26\">",
"      Grodstein F, Colditz GA, Stampfer MJ. Postmenopausal hormone use and cholecystectomy in a large prospective study. Obstet Gynecol 1994; 83:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4489/abstract/27\">",
"      Henriksson P, Einarsson K, Eriksson A, et al. Estrogen-induced gallstone formation in males. Relation to changes in serum and biliary lipids during hormonal treatment of prostatic carcinoma. J Clin Invest 1989; 84:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4489/abstract/28\">",
"      Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4489/abstract/29\">",
"      Cirillo DJ, Wallace RB, Rodabough RJ, et al. Effect of estrogen therapy on gallbladder disease. JAMA 2005; 293:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4489/abstract/30\">",
"      Liu B, Beral V, Balkwill A, et al. Gallbladder disease and use of transdermal versus oral hormone replacement therapy in postmenopausal women: prospective cohort study. BMJ 2008; 337:a386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4489/abstract/31\">",
"      Gallbladder disease as a side effect of drugs influencing lipid metabolism. Experience in the Coronary Drug Project. N Engl J Med 1977; 296:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4489/abstract/32\">",
"      Strom BL, Tamragouri RN, Morse ML, et al. Oral contraceptives and other risk factors for gallbladder disease. Clin Pharmacol Ther 1986; 39:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4489/abstract/33\">",
"      Scragg RK, McMichael AJ, Seamark RF. Oral contraceptives, pregnancy, and endogenous oestrogen in gall stone disease--a case-control study. Br Med J (Clin Res Ed) 1984; 288:1795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4489/abstract/34\">",
"      Thijs C, Leffers P, Knipschild P. Oral contraceptive use and the occurrence of gallstone disease--a case-control study. Prev Med 1993; 22:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4489/abstract/35\">",
"      Thijs C, Knipschild P. Oral contraceptives and the risk of gallbladder disease: a meta-analysis. Am J Public Health 1993; 83:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4489/abstract/36\">",
"      Gilat T, Feldman C, Halpern Z, et al. An increased familial frequency of gallstones. Gastroenterology 1983; 84:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4489/abstract/37\">",
"      Sarin SK, Negi VS, Dewan R, et al. High familial prevalence of gallstones in the first-degree relatives of gallstone patients. Hepatology 1995; 22:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4489/abstract/38\">",
"      Willett WC, Dietz WH, Colditz GA. Guidelines for healthy weight. N Engl J Med 1999; 341:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4489/abstract/39\">",
"      Friedman GD, Kannel WB, Dawber TR. The epidemiology of gallbladder disease: observations in the Framingham Study. J Chronic Dis 1966; 19:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4489/abstract/40\">",
"      Mabee TM, Meyer P, DenBesten L, Mason EE. The mechanism of increased gallstone formation in obese human subjects. Surgery 1976; 79:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4489/abstract/41\">",
"      Stampfer MJ, Maclure KM, Colditz GA, et al. Risk of symptomatic gallstones in women with severe obesity. Am J Clin Nutr 1992; 55:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4489/abstract/42\">",
"      Scragg RK, McMichael AJ, Baghurst PA. Diet, alcohol, and relative weight in gall stone disease: a case-control study. Br Med J (Clin Res Ed) 1984; 288:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4489/abstract/43\">",
"      J&oslash;rgensen T. Prevalence of gallstones in a Danish population. Am J Epidemiol 1987; 126:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4489/abstract/44\">",
"      Amaral JF, Thompson WR. Gallbladder disease in the morbidly obese. Am J Surg 1985; 149:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4489/abstract/45\">",
"      Liddle RA, Goldstein RB, Saxton J. Gallstone formation during weight-reduction dieting. Arch Intern Med 1989; 149:1750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4489/abstract/46\">",
"      Broomfield PH, Chopra R, Sheinbaum RC, et al. Effects of ursodeoxycholic acid and aspirin on the formation of lithogenic bile and gallstones during loss of weight. N Engl J Med 1988; 319:1567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4489/abstract/47\">",
"      Shiffman ML, Kaplan GD, Brinkman-Kaplan V, Vickers FF. Prophylaxis against gallstone formation with ursodeoxycholic acid in patients participating in a very-low-calorie diet program. Ann Intern Med 1995; 122:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4489/abstract/48\">",
"      Shiffman ML, Sugerman HJ, Kellum JM, Moore EW. Changes in gallbladder bile composition following gallstone formation and weight reduction. Gastroenterology 1992; 103:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4489/abstract/49\">",
"      De Santis A, Attili AF, Ginanni Corradini S, et al. Gallstones and diabetes: a case-control study in a free-living population sample. Hepatology 1997; 25:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4489/abstract/50\">",
"      Chapman BA, Wilson IR, Frampton CM, et al. Prevalence of gallbladder disease in diabetes mellitus. Dig Dis Sci 1996; 41:2222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4489/abstract/51\">",
"      Ruhl CE, Everhart JE. Association of diabetes, serum insulin, and C-peptide with gallbladder disease. Hepatology 2000; 31:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4489/abstract/52\">",
"      Biddinger SB, Haas JT, Yu BB, et al. Hepatic insulin resistance directly promotes formation of cholesterol gallstones. Nat Med 2008; 14:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4489/abstract/53\">",
"      Hahm JS, Park JY, Park KG, et al. Gallbladder motility in diabetes mellitus using real time ultrasonography. Am J Gastroenterol 1996; 91:2391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4489/abstract/54\">",
"      Thijs C, Knipschild P, Brombacher P. Serum lipids and gallstones: a case-control study. Gastroenterology 1990; 99:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4489/abstract/55\">",
"      Scragg RK, Calvert GD, Oliver JR. Plasma lipids and insulin in gall stone disease: a case-control study. Br Med J (Clin Res Ed) 1984; 289:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4489/abstract/56\">",
"      Halldestam I, Kullman E, Borch K. Incidence of and potential risk factors for gallstone disease in a general population sample. Br J Surg 2009; 96:1315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4489/abstract/57\">",
"      Marks JW, Cleary PA, Albers JJ. Lack of correlation between serum lipoproteins and biliary cholesterol saturation in patients with gallstones. Dig Dis Sci 1984; 29:1118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4489/abstract/58\">",
"      Conte D, Fraquelli M, Fornari F, et al. Close relation between cirrhosis and gallstones: cross-sectional and longitudinal survey. Arch Intern Med 1999; 159:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4489/abstract/59\">",
"      Alvaro D, Angelico M, Gandin C, et al. Physico-chemical factors predisposing to pigment gallstone formation in liver cirrhosis. J Hepatol 1990; 10:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4489/abstract/60\">",
"      Stauber RE, Rosenblum E, Eagon PK, et al. The effect of portal-systemic shunting on hepatic sex hormone receptors in male rats. Gastroenterology 1991; 100:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4489/abstract/61\">",
"      Acalovschi M, Dumitracu DL, Csakany I. Gastric and gall bladder emptying of a mixed meal are not coordinated in liver cirrhosis--a simultaneous sonographic study. Gut 1997; 40:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4489/abstract/62\">",
"      Apstein MD, Dalecki-Chipperfield K. Spinal cord injury is a risk factor for gallstone disease. Gastroenterology 1987; 92:966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4489/abstract/63\">",
"      Quigley EM, Marsh MN, Shaffer JL, Markin RS. Hepatobiliary complications of total parenteral nutrition. Gastroenterology 1993; 104:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4489/abstract/64\">",
"      Nightingale JM, Lennard-Jones JE, Gertner DJ, et al. Colonic preservation reduces need for parenteral therapy, increases incidence of renal stones, but does not change high prevalence of gall stones in patients with a short bowel. Gut 1992; 33:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4489/abstract/65\">",
"      Hussaini SH, Murphy GM, Kennedy C, et al. The role of bile composition and physical chemistry in the pathogenesis of octreotide-associated gallbladder stones. Gastroenterology 1994; 107:1503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4489/abstract/66\">",
"      Ezzat S, Snyder PJ, Young WF, et al. Octreotide treatment of acromegaly. A randomized, multicenter study. Ann Intern Med 1992; 117:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4489/abstract/67\">",
"      Newman CB, Melmed S, Snyder PJ, et al. Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients--a clinical research center study. J Clin Endocrinol Metab 1995; 80:2768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4489/abstract/68\">",
"      St&aring;hlberg D, Reihn&eacute;r E, Rudling M, et al. Influence of bezafibrate on hepatic cholesterol metabolism in gallstone patients: reduced activity of cholesterol 7 alpha-hydroxylase. Hepatology 1995; 21:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4489/abstract/69\">",
"      Arvidsson A, Alv&aacute;n G, Angelin B, et al. Ceftriaxone: renal and biliary excretion and effect on the colon microflora. J Antimicrob Chemother 1982; 10:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4489/abstract/70\">",
"      Shiffman ML, Keith FB, Moore EW. Pathogenesis of ceftriaxone-associated biliary sludge. In vitro studies of calcium-ceftriaxone binding and solubility. Gastroenterology 1990; 99:1772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4489/abstract/71\">",
"      Leitzmann MF, Giovannucci EL, Rimm EB, et al. The relation of physical activity to risk for symptomatic gallstone disease in men. Ann Intern Med 1998; 128:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4489/abstract/72\">",
"      Leitzmann MF, Rimm EB, Willett WC, et al. Recreational physical activity and the risk of cholecystectomy in women. N Engl J Med 1999; 341:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4489/abstract/73\">",
"      Lapidus A, B&aring;ngstad M, Astr&ouml;m M, Muhrbeck O. The prevalence of gallstone disease in a defined cohort of patients with Crohn's disease. Am J Gastroenterol 1999; 94:1261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4489/abstract/74\">",
"      Brink MA, Slors JF, Keulemans YC, et al. Enterohepatic cycling of bilirubin: a putative mechanism for pigment gallstone formation in ileal Crohn's disease. Gastroenterology 1999; 116:1420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4489/abstract/75\">",
"      Fraquelli M, Losco A, Visentin S, et al. Gallstone disease and related risk factors in patients with Crohn disease: analysis of 330 consecutive cases. Arch Intern Med 2001; 161:2201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4489/abstract/76\">",
"      Parente F, Pastore L, Bargiggia S, et al. Incidence and risk factors for gallstones in patients with inflammatory bowel disease: a large case-control study. Hepatology 2007; 45:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4489/abstract/77\">",
"      Bodmer M, Brauchli YB, Kr&auml;henb&uuml;hl S, et al. Statin use and risk of gallstone disease followed by cholecystectomy. JAMA 2009; 302:2001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4489/abstract/78\">",
"      Erichsen R, Fr&oslash;slev T, Lash TL, et al. Long-term statin use and the risk of gallstone disease: A population-based case-control study. Am J Epidemiol 2011; 173:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4489/abstract/79\">",
"      Simon JA, Hudes ES. Serum ascorbic acid and gallbladder disease prevalence among US adults: the Third National Health and Nutrition Examination Survey (NHANES III). Arch Intern Med 2000; 160:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4489/abstract/80\">",
"      Leitzmann MF, Willett WC, Rimm EB, et al. A prospective study of coffee consumption and the risk of symptomatic gallstone disease in men. JAMA 1999; 281:2106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4489/abstract/81\">",
"      Leitzmann MF, Stampfer MJ, Willett WC, et al. Coffee intake is associated with lower risk of symptomatic gallstone disease in women. Gastroenterology 2002; 123:1823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4489/abstract/82\">",
"      Tsai CJ, Leitzmann MF, Willett WC, Giovannucci EL. Fruit and vegetable consumption and risk of cholecystectomy in women. Am J Med 2006; 119:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4489/abstract/83\">",
"      Tsai CJ, Leitzmann MF, Willett WC, Giovannucci EL. The effect of long-term intake of cis unsaturated fats on the risk for gallstone disease in men: a prospective cohort study. Ann Intern Med 2004; 141:514.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 662 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-1FB45B5B38-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_24_4489=[""].join("\n");
var outline_f4_24_4489=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Sex",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Oral contraceptives and estrogen replacement therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Family history and genetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Obesity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Rapid weight loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Serum lipids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Gallbladder stasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Other drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Decreased physical activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Crohn's disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Hemolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      PROTECTIVE FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Statins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Ascorbic acid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Coffee",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Vegetable protein",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Poly- and monounsaturated fats",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/662\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/662|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/40/40589\" title=\"figure 1\">",
"      BMI symptomatic gallstones AGA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/662|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/47/7932\" title=\"table 1\">",
"      Risk factors for gallstones",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/50/814\" title=\"table 2\">",
"      Prevalence of gallstones",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/3/18489?source=related_link\">",
"      Approach to the diagnosis of hemolytic anemia in the adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/58/41898?source=related_link\">",
"      Complications of bariatric surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/56/1923?source=related_link\">",
"      Patient information: Gallbladder removal (cholecystectomy) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/21/7507?source=related_link\">",
"      Patient information: Gallstones (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/29/8658?source=related_link\">",
"      Patient information: Gallstones (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/34/3623?source=related_link\">",
"      Somatostatinoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_24_4490="Evaluation of the survivor of sudden cardiac arrest";
var content_f4_24_4490=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of the survivor of sudden cardiac arrest",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/24/4490/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/24/4490/contributors\">",
"     Philip J Podrid, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/24/4490/contributors\">",
"     Jie Cheng, MD, PhD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/24/4490/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/24/4490/contributors\">",
"     Brian Olshansky, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/24/4490/contributors\">",
"     Scott Manaker, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/24/4490/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/24/4490/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/24/4490/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sudden cardiac arrest (SCA) and sudden cardiac death (SCD) refer to the sudden cessation of cardiac activity with hemodynamic collapse, typically due to sustained ventricular",
"    <span class=\"nowrap\">",
"     tachycardia/ventricular",
"    </span>",
"    fibrillation. These events mostly occur in patients with structural heart disease (that may not have been previously diagnosed), particularly coronary heart disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/54/16233?source=see_link\">",
"     \"Pathophysiology and etiology of sudden cardiac arrest\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The event is referred to as SCA (or aborted SCD) if an intervention (eg, defibrillation) or spontaneous reversion restores circulation. The event is called SCD if the patient dies. However, the use of SCD to describe both fatal and nonfatal cardiac arrest persists by convention. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/55/890?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of sudden cardiac arrest and sudden cardiac death\", section on 'Definitions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Evaluation of the survivor of SCD includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Identification and treatment of acute reversible causes",
"     </li>",
"     <li>",
"      Evaluation for structural heart disease",
"     </li>",
"     <li>",
"      In patients without obvious arrhythmic triggers or cardiac structural abnormalities, an evaluation for primary electrical diseases",
"     </li>",
"     <li>",
"      Neurologic and psychologic assessment",
"     </li>",
"     <li>",
"      In selected patients with a suspected or confirmed heritable syndrome, evaluation of family members",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The evaluation of the survivor of SCD will be reviewed here. The pathophysiology of SCD and the management of survivors of SCD are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/55/890?source=see_link\">",
"     \"Overview of sudden cardiac arrest and sudden cardiac death\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/54/16233?source=see_link\">",
"     \"Pathophysiology and etiology of sudden cardiac arrest\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/12/15559?source=see_link\">",
"     \"Sudden cardiac arrest in the absence of apparent structural heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43385?source=see_link\">",
"     \"Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY OF SCD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accurate and precise measures of the relative frequencies of various causes of SCD are difficult to obtain. Case definitions are inconsistent and etiologies vary according to the population studied. A detailed review of the causes of SCD is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/54/16233?source=see_link\">",
"     \"Pathophysiology and etiology of sudden cardiac arrest\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Common causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;For the purposes of this discussion, the following data are representative of the reported frequencies of the causes of out-of-hospital SCD (",
"    <a class=\"graphic graphic_table graphicRef62184 \" href=\"UTD.htm?16/52/17228\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4490/abstract/1-7\">",
"     1-7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sixty-five to 70 percent are due to coronary heart disease (CHD), including both acute ischemic events and malignant arrhythmias that occur in patients with stable CHD and prior infarctions. Among individuals with SCD before age 40, CHD is significantly less common while other types of structural heart disease and primary electrical disease are more common.",
"     </li>",
"     <li>",
"      Approximately 10 percent are due to other types of structural heart disease (eg, myocarditis, hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy).",
"     </li>",
"     <li>",
"      Five to 10 percent of arrhythmic SCD occurs in patients with structurally normal hearts.",
"     </li>",
"     <li>",
"      Fifteen to 35 percent are due to noncardiac causes (eg, trauma, bleeding, drug intoxication, intracranial hemorrhage, pulmonary embolism, near-drowning, and central airway obstruction). Patients with a clear noncardiac cause for sudden death are sometimes excluded from studies of SCD. Management of such patients is focused upon the underlying disorder, and these patients do not require evaluation for or treatment to prevent recurrent SCD.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although not specifically mentioned in most of these studies, heart failure (HF) is a relatively common cause of SCD. SCD accounts for 30 to 50 percent of deaths in patients with heart failure (HF) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4490/abstract/8\">",
"     8",
"    </a>",
"    ], and the incidence of SCD appears to be increased during periods of worsening HF symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4490/abstract/9\">",
"     9",
"    </a>",
"    ]. Although the risk of both arrhythmic and nonarrhythmic death can be reduced with appropriate chronic HF therapy, the SCD risk remains elevated. Thus, virtually all SCD survivors with HF receive an ICD. A detailed discussion of arrhythmic events and the effect of medical therapy in HF patients is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/47/21241?source=see_link\">",
"     \"Ventricular arrhythmias in heart failure and cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A specific form of ventricular tachycardia, called bundle branch reentrant ventricular tachycardia, is seen in patients with dilated cardiomyopathy and conduction abnormalities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/42/41637?source=see_link\">",
"     \"Bundle branch reentrant ventricular tachycardia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Transient or reversible causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of transient or reversible conditions may precipitate arrhythmic events and SCD. Identification of such conditions is critical both for the management of the underlying disorder and for determining the likelihood of recurrent SCD. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Initial evaluation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In some of these cases, management of the underlying disorder is all that is necessary to reduce the risk of recurrent events. However, despite an apparently reversible trigger for SCD, many patients have a persistent risk of recurrent events and may benefit from implantable cardioverter-defibrillator (ICD) therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4490/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/21/30041?source=see_link\">",
"     \"Outcome of sudden cardiac arrest\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Potentially reversible triggers for SCD include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute cardiac ischemia and myocardial infarction &ndash; Because CHD is the most common cause of SCD, acute coronary ischemia should be considered in all survivors of SCD. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30890?source=see_link\">",
"       \"Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H10\">",
"       'Coronary angiography'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Antiarrhythmic drugs &ndash; All antiarrhythmic drugs have proarrhythmic properties, particularly in patients with underlying cardiac disease [",
"      <a class=\"abstract\" href=\"UTD.htm?4/24/4490/abstract/12-14\">",
"       12-14",
"      </a>",
"      ]. Among SCD survivors who have been taking antiarrhythmic medications, it is difficult to be certain if the arrest was provoked by the drug or occurred despite its use [",
"      <a class=\"abstract\" href=\"UTD.htm?4/24/4490/abstract/15\">",
"       15",
"      </a>",
"      ]. Thus, it is often difficult to know if antiarrhythmic medications should be discontinued, increased, or adjusted. In such patients, involvement of an arrhythmia specialist is recommended.",
"     </li>",
"     <li>",
"      Medication (eg, QT prolonging drugs), toxin, or illicit drug ingestion [",
"      <a class=\"abstract\" href=\"UTD.htm?4/24/4490/abstract/16,17\">",
"       16,17",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link\">",
"       \"Acquired long QT syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Electrolyte abnormalities, most notably hypokalemia, hyperkalemia, and hypomagnesemia.",
"     </li>",
"     <li>",
"      pH changes, especially acidemia (respiratory or metabolic).",
"     </li>",
"     <li>",
"      Heart failure &ndash; The incidence of SCD appears to be increased during periods of worsening HF symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?4/24/4490/abstract/9\">",
"       9",
"      </a>",
"      ]. However, HF is a chronic disease, and although acute episodes may be managed, the condition is not truly transient or reversible. Even with appropriate chronic HF therapy, the SCD risk remains elevated. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/47/21241?source=see_link\">",
"       \"Ventricular arrhythmias in heart failure and cardiomyopathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Autonomic nervous system activation, especially sympathetic neural inputs.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     INITIAL EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation begins immediately after resuscitation. The first concern is to exclude any obvious reversible factors that may have led to the event (",
"    <a class=\"graphic graphic_table graphicRef52416 \" href=\"UTD.htm?17/18/17708\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     History and physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient (if awake) and family should be questioned, with particular attention to the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Prior diagnoses of heart disease",
"     </li>",
"     <li>",
"      Use of any medications, especially antiarrhythmic drugs, diuretics, and drugs that might produce long QT syndrome",
"     </li>",
"     <li>",
"      Ingestion of toxins or illicit drugs",
"     </li>",
"     <li>",
"      Antecedent symptoms, especially evidence of ischemia",
"     </li>",
"     <li>",
"      Antecedent stressful events or activities",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Unfortunately, the cardiac arrest is frequently unwitnessed. In addition, the patient resuscitated from VF often has retrograde amnesia and is unable to remember what occurred prior to the cardiac arrest. Thus, a coherent history may not be ascertainable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immediate evaluation should include standard laboratory testing and, in many cases, an arterial blood gas to exclude electrolyte abnormalities and acidosis. Any reversible metabolic abnormalities should be identified and corrected, particularly hypokalemia and hypomagnesemia which can predispose to ventricular tachyarrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4490/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When interpreting the test results, two important limitations should be considered:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Electrolyte abnormalities during and shortly after resuscitation may be secondary to cardiac arrest and hypoperfusion as opposed to a cause of SCD [",
"      <a class=\"abstract\" href=\"UTD.htm?4/24/4490/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Electrolyte abnormalities by themselves are usually insufficient to cause SCD. Clinical settings that increase the proarrhythmic effect of hypokalemia and hypomagnesemia include acute myocardial infarction [",
"      <a class=\"abstract\" href=\"UTD.htm?4/24/4490/abstract/21\">",
"       21",
"      </a>",
"      ] and long QT syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link&amp;anchor=H14#H14\">",
"       \"Acquired long QT syndrome\", section on 'Hypokalemia, hypomagnesemia, and hypocalcemia'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is potentially hazardous to ascribe a cardiac arrest to an electrolyte or metabolic derangement alone, unless there is compelling evidence of an association. Mistaken attribution of a major arrhythmia to an innocent or merely potentiating laboratory abnormality can place the patient at high risk if appropriate therapy to prevent recurrent SCD is delayed or not given.",
"   </p>",
"   <p>",
"    This risk was illustrated in a review of 169 patients treated with an ICD for sustained ventricular arrhythmia in whom the plasma potassium concentration was measured on the day of the arrhythmia [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4490/abstract/22\">",
"     22",
"    </a>",
"    ]. The likelihood of a recurrent sustained ventricular arrhythmia was 82 percent at five years. The long-term risk was similar in patients with low, normal, and high plasma potassium concentrations at presentation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Electrocardiogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ECG can reveal evidence of both acute abnormalities and chronic conditions. It should be part of the immediate evaluation and repeated as necessary once the patient's cardiac, hemodynamic, and metabolic condition stabilizes [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4490/abstract/23\">",
"     23",
"    </a>",
"    ]. The ECG should be evaluated for evidence of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ongoing ischemia or prior myocardial infarction. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Coronary angiography'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/24/11658?source=see_link\">",
"       \"Electrocardiogram in the diagnosis of myocardial ischemia and infarction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Conduction system disease, including bundle branch block, second degree heart block, and third degree heart block. (See appropriate topic reviews).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Less common abnormalities that also may be evident include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Brugada syndrome, evidenced by a pseudo-RBBB and persistent ST segment elevation in V1 to V3 (",
"      <a class=\"graphic graphic_waveform graphicRef64510 \" href=\"UTD.htm?8/35/8762\">",
"       waveform 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28250?source=see_link\">",
"       \"Brugada syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Wolff-Parkinson-White syndrome (",
"      <a class=\"graphic graphic_waveform graphicRef75578 \" href=\"UTD.htm?34/55/35706\">",
"       waveform 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/61/17370?source=see_link&amp;anchor=H13260510#H13260510\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of the Wolff-Parkinson-White syndrome\", section on 'Electrocardiographic (ECG) findings'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Arrhythmogenic right ventricular cardiomyopathy (ARVC), suggested by VT or ventricular ectopy with a left bundle branch block configuration and an inferior axis. In addition, abnormalities of the baseline QRS may be present, including an epsilon wave in the right precordial leads (",
"      <a class=\"graphic graphic_waveform graphicRef56591 graphicRef60781 \" href=\"UTD.htm?39/24/40330\">",
"       waveform 3A-B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/22/32106?source=see_link&amp;anchor=H8#H8\">",
"       \"Clinical manifestations and diagnosis of arrhythmogenic right ventricular cardiomyopathy\", section on 'Evaluation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Long QT syndrome (",
"      <a class=\"graphic graphic_waveform graphicRef77018 \" href=\"UTD.htm?26/24/27008\">",
"       waveform 4",
"      </a>",
"      ), possibly with torsades de pointes (",
"      <a class=\"graphic graphic_waveform graphicRef53891 \" href=\"UTD.htm?42/23/43380\">",
"       waveform 5",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2202?source=see_link\">",
"       \"Clinical features of congenital long QT syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link\">",
"       \"Acquired long QT syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hypertrophic cardiomyopathy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/3/22586?source=see_link\">",
"       \"Ventricular arrhythmias and sudden cardiac arrest in hypertrophic cardiomyopathy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36522?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     EVALUATION FOR STRUCTURAL HEART DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Excluding patients with an obvious noncardiac etiology (eg, trauma, hemorrhage, or pulmonary embolus), structural heart disease is present in up to 90 percent of patients with SCD (",
"    <a class=\"graphic graphic_table graphicRef62184 \" href=\"UTD.htm?16/52/17228\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4490/abstract/1-7\">",
"     1-7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/54/16233?source=see_link\">",
"     \"Pathophysiology and etiology of sudden cardiac arrest\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is essential that all survivors of SCD undergo a complete cardiac examination to determine the nature and extent of underlying heart disease. The initial history, physical examination, and laboratory tests may provide evidence of one of these disorders, but further testing is usually necessary to confirm a diagnosis.",
"   </p>",
"   <p>",
"    The standard evaluation typically includes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      ECG (see",
"      <a class=\"local\" href=\"#H8\">",
"       'Electrocardiogram'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Cardiac catheterization with coronary angiography",
"     </li>",
"     <li>",
"      Echocardiography",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the appropriate clinical setting, coronary angiography and echocardiography may be part of the urgent initial evaluation.",
"   </p>",
"   <p>",
"    In selected patients, cardiac magnetic resonance imaging (MRI) and, rarely, myocardial biopsy are performed. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Cardiac MR'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Coronary angiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coronary angiography is performed in most survivors of SCD for one of two indications: management of an acute coronary syndrome or diagnosis of chronic CHD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Acute coronary syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;SCD may be the presenting manifestation of an acute coronary syndrome (ACS). Among patients with an ACS, malignant arrhythmias are significantly more common in the setting of an acute ST elevation MI (STEMI), but are also seen in approximately 2 percent of patients with a non-ST elevation MI (NSTEMI). In patients with an ACS and ischemia, the arrhythmia is usually polymorphic VT, rapid VT (ventricular flutter), or VF. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30890?source=see_link\">",
"     \"Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A patient with evidence of an STEMI following resuscitation from SCD should undergo urgent cardiac catheterization and primary PCI as appropriate. Similarly, patients with a confirmed or suspected NSTEMI should also undergo cardiac catheterization with revascularization as indicated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/46/16106?source=see_link\">",
"     \"Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29722?source=see_link\">",
"     \"Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who experience SCD during the first 48 hours after an STEMI have a higher in-hospital mortality compared to STEMI patients who do not experience sustained VT or VF. However, among patients who survive to hospital discharge there is little or no difference in mortality at one to two years. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30890?source=see_link\">",
"     \"Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Diagnostic angiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;In SCD survivors without an ACS, angiography is still considered to exclude stable, chronic CHD [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4490/abstract/23\">",
"     23",
"    </a>",
"    ]. Malignant arrhythmias and SCD occur in such patients, usually those who have had a prior infarction with residual myocardial scar. In contrast to patients with an ACS, the culprit arrhythmia is usually scar-related monomorphic VT, which is not the result of ischemia. However, monomorphic VT can ultimately degenerate to VF, particularly if the arrhythmia induces ischemia. Because SCD may be the first clinical evidence of chronic CHD, most SCD survivors undergo diagnostic angiography prior to discharge.",
"   </p>",
"   <p>",
"    Diagnostic coronary angiography may not be necessary in selected patients without signs or symptoms of CHD if another clear cause for SCD is identified (eg, long QT syndrome, WPW, Brugada, hypertrophic cardiomyopathy, left ventricular noncompaction, or arrhythmogenic right ventricular cardiomyopathy).",
"   </p>",
"   <p>",
"    Angiography is suggested in younger patients without an apparent cause for SCD in whom angiography may also detect an anomalous origin of a coronary artery. Among competitive athletes under age 35, anomalous origin of a coronary artery was present in 13 percent of SCD survivors in one series [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4490/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/36/13898?source=see_link&amp;anchor=H7#H7\">",
"     \"Risk of sudden cardiac death in athletes\", section on 'Etiology of sudden death'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with stable CHD who experience an episode of primary SCD without evidence of simultaneous ischemia are at high risk for recurrent malignant arrhythmias, even after percutaneous or surgical revascularization [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4490/abstract/25-28\">",
"     25-28",
"    </a>",
"    ]. As a result, such patients are treated with an ICD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/52/35658?source=see_link\">",
"     \"Risk stratification for cardiac events after acute ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/20/44361?source=see_link&amp;anchor=H23#H23\">",
"     \"Epidemiology of coronary heart disease\", section on 'Sudden cardiac death'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is unclear whether or not",
"    <strong>",
"     immediate",
"    </strong>",
"    coronary angiography to exclude an ACS should be performed in all SCD survivors without a clear alternative explanation. The value of this approach was evaluated in a consecutive series of 84 such survivors of out-of-hospital cardiac arrest, all of whom underwent urgent catheterization and angiography [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4490/abstract/3\">",
"     3",
"    </a>",
"    ]. Of these patients; 36 had ST elevation, 18 had left bundle branch block, and eight had ST depression. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Total occlusion of a coronary artery was found in 40 patients and evidence of an unstable lesion in 18.",
"     </li>",
"     <li>",
"      Nine patients without ST elevation or chest pain had at least one totally occluded coronary artery.",
"     </li>",
"     <li>",
"      Long-term outcomes were better in the 28 patients who had successful urgent PCI.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, since three-quarters of the patients had ST elevations, ST depressions, or left bundle branch block (LBBB), these results apply more directly to those SCD survivors with evidence of active ischemia. The study did not directly address the necessity of routine urgent angiography in patients without evidence of ischemia. Similar findings have been reported in another cohort of 93 patients (only 39 [42 percent] with ST elevation of LBBB) in whom survival to hospital discharge was significantly higher among patients who underwent emergency coronary angiography (hazard ratio 2.32, 95% CI 1.23-4.38) compared with those who did not undergo emergency angiography [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4490/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Echocardiography can detect abnormalities that suggest or confirm the diagnosis of many of the important causes of SCD. Since global left ventricular dysfunction due to myocardial stunning can be induced by cardiac arrest and cardiopulmonary resuscitation, evaluation of left ventricular function should be performed at least 48 hours after resuscitation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4490/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Detailed review of the diagnostic criteria for each disorder is presented separately. Potential causes of SCD that can be detected with echocardiography include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CHD &ndash; Left ventricular dysfunction with wall motion abnormalities suggest prior myocardial infarction. Dyskinetic wall motion is consistent with an aneurysm",
"     </li>",
"     <li>",
"      Hypertrophic cardiomyopathy (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36522?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Arrhythmogenic right ventricular cardiomyopathy (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/22/32106?source=see_link\">",
"       \"Clinical manifestations and diagnosis of arrhythmogenic right ventricular cardiomyopathy\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Aortic stenosis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/3/1082?source=see_link\">",
"       \"Echocardiographic evaluation of the aortic valve\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Dilated cardiomyopathy (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/12/15562?source=see_link\">",
"       \"Echocardiographic recognition of cardiomyopathies\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/47/21241?source=see_link\">",
"       \"Ventricular arrhythmias in heart failure and cardiomyopathy\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Cardiac MR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac magnetic resonance imaging (CMR) is indicated for selected patients in whom a diagnosis is uncertain after the above evaluation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34874?source=see_link\">",
"     \"Clinical utility of cardiovascular magnetic resonance imaging\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CMR is useful in the evaluation of the following disorders:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypertrophic cardiomyopathy (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36522?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Myocarditis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/16/26889?source=see_link&amp;anchor=H20#H20\">",
"       \"Clinical manifestations and diagnosis of myocarditis in adults\", section on 'Cardiovascular magnetic resonance'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Arrhythmogenic right ventricular cardiomyopathy (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/22/32106?source=see_link\">",
"       \"Clinical manifestations and diagnosis of arrhythmogenic right ventricular cardiomyopathy\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Dilated cardiomyopathy",
"     </li>",
"     <li>",
"      Congenital heart disease, including anomalous origin of coronary arteries (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/56/14218?source=see_link\">",
"       \"Congenital and pediatric coronary artery abnormalities\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/26/20906?source=see_link\">",
"       \"Noninvasive coronary imaging with cardiac computed tomography and cardiovascular magnetic resonance\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Cardiac sarcoidosis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/19/17722?source=see_link&amp;anchor=H22303008#H22303008\">",
"       \"Cardiac sarcoidosis\", section on 'Cardiovascular magnetic resonance'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Cardiac amyloidosis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/10/23722?source=see_link&amp;anchor=H2554149#H2554149\">",
"       \"Clinical manifestations and diagnosis of amyloid cardiomyopathy\", section on 'Cardiovascular magnetic resonance'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The utility of CMR angiography as an alternative to invasive coronary angiography is not well defined. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/26/20906?source=see_link\">",
"     \"Noninvasive coronary imaging with cardiac computed tomography and cardiovascular magnetic resonance\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1997, the Joint steering committees of the Unexplained Cardiac Arrest Registry of Europe and of the Idiopathic Ventricular Fibrillation Registry of the United States published recommendations for the evaluation of SCD survivors [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4490/abstract/6\">",
"     6",
"    </a>",
"    ]. These recommendations included the following tests, all of which are described above:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      History and physical examination",
"     </li>",
"     <li>",
"      Blood biochemistries",
"     </li>",
"     <li>",
"      ECG",
"     </li>",
"     <li>",
"      Echocardiography",
"     </li>",
"     <li>",
"      Coronary angiography",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Since the publication of these recommendations, cardiac MR has come into wider use and is now a common component of this evaluation when standard tests are inconclusive.",
"   </p>",
"   <p>",
"    When this evaluation has not provided a diagnosis, the patient is evaluated for primary electrical disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     EVALUATION FOR PRIMARY ELECTRICAL DISEASES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     General issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 5 to 10 percent of SCD survivors have no evidence of a noncardiac etiology or of structural heart disease after the above evaluation. Such patients are considered to have a primary electrical disorder.",
"   </p>",
"   <p>",
"    A detailed discussion of SCD in patients with a structurally normal heart is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/12/15559?source=see_link\">",
"     \"Sudden cardiac arrest in the absence of apparent structural heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The majority of these patients do not actually have \"normal\" hearts, but historically our diagnostic tools have been unable to identify the structural or functional derangement. In the past, the etiology of many of these deaths was unknown and deemed \"idiopathic.\" Subsequent discoveries have identified the cause of death in many of these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4490/abstract/5,31,32\">",
"     5,31,32",
"    </a>",
"    ]. As our understanding of the mechanisms of primary electrical disorders has improved, so have our diagnostic capabilities, with important benefits for both the victims of SCD and their families.",
"   </p>",
"   <p>",
"    These disorders are often detected by characteristic changes on the ECG (see",
"    <a class=\"local\" href=\"#H8\">",
"     'Electrocardiogram'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    Several of the disorders that cause SCD in the absence of structural heart disease are due to abnormalities of cardiac ion channels, including the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Brugada syndrome (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28250?source=see_link\">",
"       \"Brugada syndrome\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Long QT syndrome (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2202?source=see_link\">",
"       \"Clinical features of congenital long QT syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link\">",
"       \"Acquired long QT syndrome\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Short QT syndrome (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/61/19417?source=see_link\">",
"       \"Short QT syndrome\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Catecholaminergic polymorphic VT (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37641?source=see_link\">",
"       \"Catecholaminergic polymorphic ventricular tachycardia and other polymorphic ventricular tachycardias with a normal QT interval\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Disorders associated with SCD that are not due to ion channel abnormalities include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Wolff-Parkinson-White syndrome (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/61/17370?source=see_link\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of the Wolff-Parkinson-White syndrome\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Commotio cordis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/52/12101?source=see_link\">",
"       \"Commotio cordis\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients without evidence of any of the above structural or electrical abnormalities are said to have idiopathic VF or primary electrical disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/12/15559?source=see_link&amp;anchor=H11#H11\">",
"     \"Sudden cardiac arrest in the absence of apparent structural heart disease\", section on 'Idiopathic VF'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Identification of a primary electrical disorder in a SCD survivor has two important benefits:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Directing medical treatment to prevent arrhythmia recurrence (eg, beta blockers for catecholaminergic polymorphic VT). Although medical therapy alone is now uncommon in SCD survivors, adjunctive medical therapy can be useful to reduce the frequency of ICD shocks. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43385?source=see_link&amp;anchor=H12#H12\">",
"       \"Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death\", section on 'Adjunctive therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Guiding the evaluation and management of family members.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     EP study",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrophysiologic (EP) testing is not usually performed in patients with an established etiology of SCD. However, EP study can be valuable in those whose initial evaluation reveals no etiology, and in selected patients with a previously identified disorder.",
"   </p>",
"   <p>",
"    The role of EP testing in patients with known structural heart disease, including ischemic cardiomyopathy, nonischemic cardiomyopathy, Brugada syndrome, HCM, and ARVC is reviewed separately. (See appropriate topic reviews).",
"   </p>",
"   <p>",
"    In SCD survivors with an apparently normal heart, EP testing may reveal the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abnormalities of atrioventricular conduction &ndash; The presence of severe conducting system disease suggests that a serious bradyarrhythmia may have contributed to the SCD event. However, such patients typically present with syncope rather than SCD. Furthermore, even when conduction disease is identified,",
"      <span class=\"nowrap\">",
"       VT/VF",
"      </span>",
"      may be the real culprit and ventricular stimulation to induce ventricular arrhythmias may be warranted.",
"     </li>",
"     <li>",
"      An accessory pathway in patients with Wolff-Parkinson-White syndrome &ndash; An accessory pathway can result in rapid conduction of a supraventricular arrhythmia such as atrial fibrillation or atrial flutter, producing a very rapid ventricular rate that can degenerate to VF. Such patients usually have evidence of preexcitation on their ECG. If preexcitation is evident on an ECG in a survivor of SCD, EP study and ablation of the accessory pathway is usually indicated. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/61/17370?source=see_link&amp;anchor=H8471569#H8471569\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of the Wolff-Parkinson-White syndrome\", section on 'Ventricular fibrillation and sudden death'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Inducible ventricular arrhythmias &ndash; VT and VF may be induced in patients with a number of underlying cardiac abnormalities. The prognostic value of inducible arrhythmias is best established in patients with prior myocardial infarction and reduced LV systolic function. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/24/20874?source=see_link&amp;anchor=H8#H8\">",
"       \"Incidence of and risk stratification for sudden cardiac death after acute myocardial infarction\", section on 'Inducible VT/VF'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is evidence that inducible VF, particularly when induced repeatedly with nonaggressive protocols, suggests the diagnosis of idiopathic VF and may predict recurrent arrhythmic events [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4490/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. In a review of the literature, 69 percent of patients with idiopathic VF had a sustained ventricular tachyarrhythmia induced with a nonaggressive protocol; induced arrhythmia was generally polymorphic in configuration and poorly tolerated [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4490/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In some other conditions it is not clear that inducible VT or VF has prognostic significance (eg, Brugada syndrome, infiltrative diseases, HCM). Furthermore, aggressive stimulation protocols can induce polymorphic VT or VF in some individuals without cardiac disease. Thus, inducible arrhythmias can be a nonspecific finding. For this reason, the significance of inducible ventricular arrhythmias in patients with apparently normal hearts is unclear. On the other hand, the absence of inducible",
"    <span class=\"nowrap\">",
"     VT/VF",
"    </span>",
"    may not preclude ICD implantation since lack of inducibility does not predict low risk.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Myocardial scar &mdash; Substrate mapping may identify areas of scar indicating abnormal substrate and a predisposition to ventricular arrhythmia. These abnormalities are more commonly seen in patients with CHD, HCM, ARVC, or infiltrative diseases, but also occur in some cases of idiopathic VF [",
"      <a class=\"abstract\" href=\"UTD.htm?4/24/4490/abstract/35\">",
"       35",
"      </a>",
"      ]. In addition, some patients with idiopathic VF have other electrophysiologic abnormalities, including areas of slow conduction, regionally delayed repolarization, or dispersion in repolarization [",
"      <a class=\"abstract\" href=\"UTD.htm?4/24/4490/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Supraventricular arrhythmias &mdash; Patients in whom VT or VF was not well documented at the time of SCD may have another culprit arrhythmia, usually a supraventricular tachycardia (SVT). In such patients, SVT may be inducible during EP study [",
"      <a class=\"abstract\" href=\"UTD.htm?4/24/4490/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Exercise testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise testing is not usually part of the CHD evaluation in SCD survivors, since most undergo coronary angiography. However, the provocation of ischemia with exercise, independently of coronary anatomy, is of importance in the evaluation of the SCD survivor. Although angiography alone does not prove a causal relationship to SCD or the presence of ischemia, the observation that revascularization appears to improve outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4490/abstract/3,27,28\">",
"     3,27,28",
"    </a>",
"    ] means that a negative exercise test in a patient with significant coronary disease on angiography is not likely to affect the decision on revascularization.",
"   </p>",
"   <p>",
"    In patients with apparently normal hearts, exercise testing can assist in the diagnosis of long QT syndrome and catecholaminergic polymorphic VT [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4490/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/6/33897?source=see_link&amp;anchor=H17#H17\">",
"     \"Diagnosis of congenital long QT syndrome\", section on 'Exercise testing'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37641?source=see_link\">",
"     \"Catecholaminergic polymorphic ventricular tachycardia and other polymorphic ventricular tachycardias with a normal QT interval\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Ambulatory monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients without a clear etiology for SCD, ambulatory monitoring may reveal recurrent sustained or nonsustained arrhythmias. However, most patients without an established diagnosis will have an ICD placed prior to discharge, and the memory features in these devices may preclude the need for ambulatory monitoring.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Pharmacologic challenge",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, some of the primary electrical disorders may still be present despite no evidence of abnormalities on any of the preceding tests. ECG abnormalities may be intermittent or latent, and genetic testing is not yet comprehensive enough to exclude all possible disorders.",
"   </p>",
"   <p>",
"    Investigators have evaluated the role of pharmacologic challenge to elicit diagnostic ECG changes or arrhythmias in selected SCD survivors. One report included 18 SCD survivors with no evidence of structural heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4490/abstract/38\">",
"     38",
"    </a>",
"    ]. All patients had a normal ECG, echocardiogram, coronary angiography, and cardiac MR. Patients were infused with epinephrine (0.05 to 0.5",
"    <span class=\"nowrap\">",
"     microg/kg",
"    </span>",
"    per min) and then",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    (1 g over 30 minutes). Epinephrine was intended to induce catecholaminergic polymorphic VT and procainamide to induce the characteristic ECG abnormalities of Brugada syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37641?source=see_link&amp;anchor=H3#H3\">",
"     \"Catecholaminergic polymorphic ventricular tachycardia and other polymorphic ventricular tachycardias with a normal QT interval\", section on 'Catecholaminergic polymorphic VT'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28250?source=see_link\">",
"     \"Brugada syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ten patients were diagnosed with catecholaminergic polymorphic VT based upon an abnormal response to epinephrine infusion (frequent or polymorphic ventricular ectopy, nonsustained VT, or sustained VT). Four of these patients had ventricular ectopy during exercise testing, but none had sustained or nonsustained VT.",
"     </li>",
"     <li>",
"      Two patients were diagnosed with Brugada syndrome.",
"     </li>",
"     <li>",
"      Six patients were left with a diagnosis of idiopathic VF.",
"     </li>",
"     <li>",
"      Among 55 family members who were tested, eight affected members from one family were diagnosed with catecholaminergic polymorphic VT, and one relative was diagnosed with Brugada syndrome.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In summary, two-thirds of patients whose standard evaluation provided no etiology for SCD had a diagnosis established with pharmacologic provocative testing. This allowed for the addition of appropriate adjunctive therapy (beta blockers for catecholaminergic polymorphic VT) and the identification of nine additional affected family members.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     MINOR CARDIAC ABNORMALITIES NOT ASSOCIATED WITH SCD",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the course of the cardiac evaluation, minor cardiac abnormalities are often detected that do not have a clear causal relationship to SCD. These findings do not preclude the diagnosis of idiopathic VF; however, their severity must be considered and monitoring is warranted since these disorders may be the initial manifestations of an underlying structural heart disease that will become clinically apparent at a later date [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4490/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Disorders such as first degree atrioventricular (AV) block, transient second degree Mobitz type II AV block without bradycardia, and isolated bundle branch block do not exclude idiopathic VF.",
"     </li>",
"     <li>",
"      Thickening of the left ventricle less than 10 percent above normal and hypertension without LV hypertrophy are not clearly associated with SCD.",
"     </li>",
"     <li>",
"      A direct link between mitral valve prolapse and SCD has not been established unless there is valve redundancy or thickening, a family history of SCD, or perhaps significant mitral regurgitation, QT interval prolongation, or ST-T waves changes. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/19/17719?source=see_link\">",
"       \"Arrhythmic complications of mitral valve prolapse\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      AF in the absence of ventricular preexcitation or hyperthyroidism is associated with an increase in total mortality, but not SCD [",
"      <a class=\"abstract\" href=\"UTD.htm?4/24/4490/abstract/6,39\">",
"       6,39",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28522?source=see_link\">",
"       \"Epidemiology of and risk factors for atrial fibrillation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Isolated ventricular premature beats are associated with an increased risk of subsequent SCD only in patients with structural heart disease or with risk factors for CHD. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/36/36424?source=see_link\">",
"       \"Clinical significance and treatment of ventricular premature beats\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     EVALUATION OF FAMILY MEMBERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some causes of SCD are familial, including a genetic predisposition to premature coronary heart disease, and the risk of cardiovascular disease appears significantly higher in first- and second-degree relatives of the SCD victims, particularly young victims. In a nationwide Danish study from 2000 to 2006, 470 victims of SCD were identified who were 35 years of age or younger [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4490/abstract/40\">",
"     40",
"    </a>",
"    ]. Among a cohort of 3073 first- and second-degree relatives of the SCD victims who were followed for up to 11 years, cardiovascular disease (CVD) was significantly more likely to be present than in the general population (standardized incidence ratio [SIR] for CVD 3.5, 95% CI 2.7-4.7). In contrast, among relatives of elderly (greater than 60 years of age) victims of SCD, there was no difference in the rates of CVD compared with the general population (SIR 0.9, 95% CI 0.8-1.1).",
"   </p>",
"   <p>",
"    A general cardiologic evaluation of first- and second-degree relatives of victims of unexplained SCD can yield the diagnosis of a heritable disease in up to 40 percent of families as illustrated by the following observations.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study or 32 families of victims of unexplained SCD, a general cardiologic evaluation (ECG, echocardiogram, Holter monitor and, less commonly, stress testing) was completed in 107 first-degree relatives [",
"      <a class=\"abstract\" href=\"UTD.htm?4/24/4490/abstract/41\">",
"       41",
"      </a>",
"      ]. Seven families (22 percent) were diagnosed with a heritable disease: four with long QT syndrome, one with nonstructural cardiac disease, one with myotonic dystrophy, and one with HCM.",
"     </li>",
"     <li>",
"      These findings were extended in a second report that evaluated 43 families with 183 surviving first- and second-degree relatives of victims of unexplained SCD at age &le;40 [",
"      <a class=\"abstract\" href=\"UTD.htm?4/24/4490/abstract/42\">",
"       42",
"      </a>",
"      ]. Careful history identified 26 additional cases of unexplained SCD at age &le;40. Cardiology evaluation included ECG, echocardiogram, exercise tolerance testing (ETT), and measurement of serum lipids. Additional testing, as indicated, included",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"       flecainide",
"      </a>",
"      challenge for suspected Brugada syndrome or cardiac MR for suspected ARVC. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28250?source=see_link\">",
"       \"Brugada syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/22/32106?source=see_link\">",
"       \"Clinical manifestations and diagnosis of arrhythmogenic right ventricular cardiomyopathy\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      When a clinical diagnosis was established, genetic testing for the suspected disease was performed. Where a genetic abnormality was confirmed, additional screening was done in another 150 family members. The following findings were noted:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A heritable disease was identified in 17 families (40 percent): five with catecholaminergic polymorphic VT, four with long QT syndrome, two with Brugada syndrome, one with",
"      <span class=\"nowrap\">",
"       Brugada/long",
"      </span>",
"      QT syndrome, three with ARVC, one with HCM, and one with familial hypercholesterolemia. Genetic analysis confirmed the diagnosis in 10 families.",
"     </li>",
"     <li>",
"      An average of 8.9 asymptomatic carriers per family was identified, many through the secondary genetic analysis.",
"     </li>",
"     <li>",
"      Identification of a specific disease was more likely if &ge;2 unexplained SCD events occurred in the family, and if more family members underwent evaluation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The increased yield in the second study may reflect the more extensive evaluation, including ETT, and the inclusion of more family members.",
"   </p>",
"   <p>",
"    Consistent with these findings, it has been recommended that first-degree family members of patients with SCD in the absence of structural heart be informed of the potentially increased risk and that an assessment should be offered at a center with experience in the diagnosis and management of inherited cardiac diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4490/abstract/32\">",
"     32",
"    </a>",
"    ]. Routine genetic screening for inherited disorders is not feasible although, in the presence of an identifiable condition, the genetic evaluation of family members may be undertaken at some centers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     NEUROLOGIC AND PSYCHOLOGIC ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have been resuscitated from sudden death should be given a complete neurologic examination to establish the nature and extent of impairment resulting from the arrest. The physical examination, rather than imaging studies or other testing, is the most useful way of elucidating the patient's degree of neurologic function and of determining prognosis. A 2004 meta-analysis of 11 studies found that the following clinical signs predicted a poor clinical outcome following cardiac arrest with 97 percent specificity [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4490/abstract/43\">",
"     43",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Absence of pupillary light response after 24 hours",
"     </li>",
"     <li>",
"      Absence of corneal reflex after 24 hours",
"     </li>",
"     <li>",
"      Absent motor responses to pain after 24 hours",
"     </li>",
"     <li>",
"      Absent motor responses after 72 hours",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/56/19337?source=see_link\">",
"     \"Hypoxic-ischemic brain injury: Evaluation and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Equally important is an assessment of the patient's psychologic state. Posttraumatic stress disorder (PTSD) may occur in SCD survivors. This was suggested in a study of 143 patients who had been resuscitated and discharged with no or only moderate neurologic disability [",
"    <a class=\"abstract\" href=\"UTD.htm?4/24/4490/abstract/44\">",
"     44",
"    </a>",
"    ]. All patients completed a self-rating questionnaire at a mean of 45 months after cardiac arrest: 39 (27 percent) fulfilled criteria for PTSD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27352?source=see_link\">",
"     \"Posttraumatic stress disorder: Epidemiology, pathophysiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33239?source=see_link\">",
"     \"Pharmacotherapy for posttraumatic stress disorder\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;At present, most survivors of SCD are treated with an ICD. The use of ICDs in SCD survivors, the role of adjunctive antiarrhythmic medications and catheter ablation, and exceptions to the use of ICDs are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43385?source=see_link\">",
"     \"Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33525015\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation of the survivor of SCD includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Identification and treatment of acute reversible causes, including (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Etiology of SCD'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Acute cardiac ischemia and myocardial infarction",
"     </li>",
"     <li>",
"      Antiarrhythmic drugs or other medication (eg, QT prolonging drugs), toxin, or illicit drug ingestion",
"     </li>",
"     <li>",
"      Electrolyte abnormalities, most notably hypokalemia, hyperkalemia, and hypomagnesemia",
"     </li>",
"     <li>",
"      Heart failure",
"     </li>",
"     <li>",
"      Autonomic nervous system factors, especially sympathetic activation (eg, physical or psychologic stress)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Evaluation for structural heart disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Initial evaluation including history, physical examination, laboratory testing (eg, electrolytes, blood gas, toxin screen, etc), and electrocardiogram (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Initial evaluation'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Evaluation for structural heart disease, which may include one or more of echocardiography, coronary angiography, cardiac magnetic resonance imaging, depending of the clinical scenario (see",
"      <a class=\"local\" href=\"#H9\">",
"       'Evaluation for structural heart disease'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients without obvious arrhythmic triggers or cardiac structural abnormalities, an evaluation for primary electrical diseases",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Primary electrical diseases include Brugada syndrome, long QT syndrome, short QT syndrome, Wolff-Parkinson-White, catecholaminergic polymorphic VT, commotio cordis, and idiopathic ventricular fibrillation (see",
"      <a class=\"local\" href=\"#H17\">",
"       'General issues'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      The evaluation for primary electrical disease may include one or more of electrophysiology studies, exercise testing, ambulatory ECG monitoring, and pharmacologic challenge (see",
"      <a class=\"local\" href=\"#H16\">",
"       'Evaluation for primary electrical diseases'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neurologic and psychologic assessment (see",
"      <a class=\"local\" href=\"#H24\">",
"       'Neurologic and psychologic assessment'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      In selected patients with a suspected or confirmed heritable syndrome, evaluation of family members (see",
"      <a class=\"local\" href=\"#H23\">",
"       'Evaluation of family members'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4490/abstract/1\">",
"      Centers for Disease Control and Prevention (CDC). State-specific mortality from sudden cardiac death--United States, 1999. MMWR Morb Mortal Wkly Rep 2002; 51:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4490/abstract/2\">",
"      Zheng ZJ, Croft JB, Giles WH, Mensah GA. Sudden cardiac death in the United States, 1989 to 1998. Circulation 2001; 104:2158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4490/abstract/3\">",
"      Spaulding CM, Joly LM, Rosenberg A, et al. Immediate coronary angiography in survivors of out-of-hospital cardiac arrest. N Engl J Med 1997; 336:1629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4490/abstract/4\">",
"      Drory Y, Turetz Y, Hiss Y, et al. Sudden unexpected death in persons less than 40 years of age. Am J Cardiol 1991; 68:1388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4490/abstract/5\">",
"      Chugh SS, Kelly KL, Titus JL. Sudden cardiac death with apparently normal heart. Circulation 2000; 102:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4490/abstract/6\">",
"      Survivors of out-of-hospital cardiac arrest with apparently normal heart. Need for definition and standardized clinical evaluation. Consensus Statement of the Joint Steering Committees of the Unexplained Cardiac Arrest Registry of Europe and of the Idiopathic Ventricular Fibrillation Registry of the United States. Circulation 1997; 95:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4490/abstract/7\">",
"      Kuisma M, Alasp&auml;&auml; A. Out-of-hospital cardiac arrests of non-cardiac origin. Epidemiology and outcome. Eur Heart J 1997; 18:1122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4490/abstract/8\">",
"      Narang R, Cleland JG, Erhardt L, et al. Mode of death in chronic heart failure. A request and proposition for more accurate classification. Eur Heart J 1996; 17:1390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4490/abstract/9\">",
"      Cleland JG, Erhardt L, Murray G, et al. Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure. A report from the AIRE Study Investigators. Eur Heart J 1997; 18:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4490/abstract/10\">",
"      Wyse DG, Friedman PL, Brodsky MA, et al. Life-threatening ventricular arrhythmias due to transient or correctable causes: high risk for death in follow-up. J Am Coll Cardiol 2001; 38:1718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4490/abstract/11\">",
"      Viskin S, Halkin A, Olgin JE. Treatable causes of sudden death: not really \"treatable\" or not really the cause? J Am Coll Cardiol 2001; 38:1725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4490/abstract/12\">",
"      Velebit V, Podrid P, Lown B, et al. Aggravation and provocation of ventricular arrhythmias by antiarrhythmic drugs. Circulation 1982; 65:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4490/abstract/13\">",
"      Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991; 324:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4490/abstract/14\">",
"      Flaker GC, Blackshear JL, McBride R, et al. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol 1992; 20:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4490/abstract/15\">",
"      Ruskin JN, McGovern B, Garan H, et al. Antiarrhythmic drugs: a possible cause of out-of-hospital cardiac arrest. N Engl J Med 1983; 309:1302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4490/abstract/16\">",
"      Kloner RA, Hale S, Alker K, Rezkalla S. The effects of acute and chronic cocaine use on the heart. Circulation 1992; 85:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4490/abstract/17\">",
"      Bauman JL, Grawe JJ, Winecoff AP, Hariman RJ. Cocaine-related sudden cardiac death: a hypothesis correlating basic science and clinical observations. J Clin Pharmacol 1994; 34:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4490/abstract/18\">",
"      Siscovick DS, Raghunathan TE, Psaty BM, et al. Diuretic therapy for hypertension and the risk of primary cardiac arrest. N Engl J Med 1994; 330:1852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4490/abstract/19\">",
"      Hoes AW, Grobbee DE, Lubsen J, et al. Diuretics, beta-blockers, and the risk for sudden cardiac death in hypertensive patients. Ann Intern Med 1995; 123:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4490/abstract/20\">",
"      Salerno DM, Asinger RW, Elsperger J, et al. Frequency of hypokalemia after successfully resuscitated out-of-hospital cardiac arrest compared with that in transmural acute myocardial infarction. Am J Cardiol 1987; 59:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4490/abstract/21\">",
"      Gettes LS. Electrolyte abnormalities underlying lethal and ventricular arrhythmias. Circulation 1992; 85:I70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4490/abstract/22\">",
"      Michaud GF, Sticherling C, Tada H, et al. Relationship between serum potassium concentration and risk of recurrent ventricular tachycardia or ventricular fibrillation. J Cardiovasc Electrophysiol 2001; 12:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4490/abstract/23\">",
"      European Heart Rhythm Association, Heart Rhythm Society, Zipes DP, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol 2006; 48:e247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4490/abstract/24\">",
"      Maron BJ, Carney KP, Lever HM, et al. Relationship of race to sudden cardiac death in competitive athletes with hypertrophic cardiomyopathy. J Am Coll Cardiol 2003; 41:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4490/abstract/25\">",
"      Natale A, Sra J, Axtell K, et al. Ventricular fibrillation and polymorphic ventricular tachycardia with critical coronary artery stenosis: does bypass surgery suffice? J Cardiovasc Electrophysiol 1994; 5:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4490/abstract/26\">",
"      Daoud EG, Niebauer M, Kou WH, et al. Incidence of implantable defibrillator discharges after coronary revascularization in survivors of ischemic sudden cardiac death. Am Heart J 1995; 130:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4490/abstract/27\">",
"      Every NR, Fahrenbruch CE, Hallstrom AP, et al. Influence of coronary bypass surgery on subsequent outcome of patients resuscitated from out of hospital cardiac arrest. J Am Coll Cardiol 1992; 19:1435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4490/abstract/28\">",
"      Kelly P, Ruskin JN, Vlahakes GJ, et al. Surgical coronary revascularization in survivors of prehospital cardiac arrest: its effect on inducible ventricular arrhythmias and long-term survival. J Am Coll Cardiol 1990; 15:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4490/abstract/29\">",
"      Zanuttini D, Armellini I, Nucifora G, et al. Impact of emergency coronary angiography on in-hospital outcome of unconscious survivors after out-of-hospital cardiac arrest. Am J Cardiol 2012; 110:1723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4490/abstract/30\">",
"      Kern KB, Hilwig RW, Rhee KH, Berg RA. Myocardial dysfunction after resuscitation from cardiac arrest: an example of global myocardial stunning. J Am Coll Cardiol 1996; 28:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4490/abstract/31\">",
"      Myerburg RJ. Sudden cardiac death in persons with normal (or near normal) hearts. Am J Cardiol 1997; 79:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4490/abstract/32\">",
"      Wever EF, Robles de Medina EO. Sudden death in patients without structural heart disease. J Am Coll Cardiol 2004; 43:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4490/abstract/33\">",
"      Viskin S, Belhassen B. Idiopathic ventricular fibrillation. Am Heart J 1990; 120:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4490/abstract/34\">",
"      DiCarlo LA Jr, Morady F, Schwartz AB, et al. Clinical significance of ventricular fibrillation-flutter induced by ventricular programmed stimulation. Am Heart J 1985; 109:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4490/abstract/35\">",
"      Josephson ME, Horowitz LN, Spielman SR, et al. Comparison of endocardial catheter mapping with intraoperative mapping of ventricular tachycardia. Circulation 1980; 61:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4490/abstract/36\">",
"      Peeters HA, Sippensgroenewegen A, Wever EF, et al. Electrocardiographic identification of abnormal ventricular depolarization and repolarization in patients with idiopathic ventricular fibrillation. J Am Coll Cardiol 1998; 31:1406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4490/abstract/37\">",
"      Becker R, Melkumov M, Senges-Becker JC, et al. Are electrophysiological studies needed prior to defibrillator implantation? Pacing Clin Electrophysiol 2003; 26:1715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4490/abstract/38\">",
"      Krahn AD, Gollob M, Yee R, et al. Diagnosis of unexplained cardiac arrest: role of adrenaline and procainamide infusion. Circulation 2005; 112:2228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4490/abstract/39\">",
"      Kannel WB, Thomas HE Jr. Sudden coronary death: the Framingham Study. Ann N Y Acad Sci 1982; 382:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4490/abstract/40\">",
"      Ranthe MF, Winkel BG, Andersen EW, et al. Risk of cardiovascular disease in family members of young sudden cardiac death victims. Eur Heart J 2013; 34:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4490/abstract/41\">",
"      Behr E, Wood DA, Wright M, et al. Cardiological assessment of first-degree relatives in sudden arrhythmic death syndrome. Lancet 2003; 362:1457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4490/abstract/42\">",
"      Tan HL, Hofman N, van Langen IM, et al. Sudden unexplained death: heritability and diagnostic yield of cardiological and genetic examination in surviving relatives. Circulation 2005; 112:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4490/abstract/43\">",
"      Booth CM, Boone RH, Tomlinson G, Detsky AS. Is this patient dead, vegetative, or severely neurologically impaired? Assessing outcome for comatose survivors of cardiac arrest. JAMA 2004; 291:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/24/4490/abstract/44\">",
"      Gamper G, Willeit M, Sterz F, et al. Life after death: posttraumatic stress disorder in survivors of cardiac arrest--prevalence, associated factors, and the influence of sedation and analgesia. Crit Care Med 2004; 32:378.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 970 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-202.43.93.2-481E12C6DB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_24_4490=[""].join("\n");
var outline_f4_24_4490=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H33525015\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY OF SCD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Common causes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Transient or reversible causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      INITIAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      History and physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Electrocardiogram",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      EVALUATION FOR STRUCTURAL HEART DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Coronary angiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Acute coronary syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Diagnostic angiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Echocardiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Cardiac MR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      EVALUATION FOR PRIMARY ELECTRICAL DISEASES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      General issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      EP study",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Exercise testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Ambulatory monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Pharmacologic challenge",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      MINOR CARDIAC ABNORMALITIES NOT ASSOCIATED WITH SCD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      EVALUATION OF FAMILY MEMBERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      NEUROLOGIC AND PSYCHOLOGIC ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33525015\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/970\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/970|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/52/17228\" title=\"table 1\">",
"      Major causes of sudden death",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/18/17708\" title=\"table 2\">",
"      Treatable conditions associated with cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/970|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?8/35/8762\" title=\"waveform 1\">",
"      ECG Brugada syndrome type I pattern",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?34/55/35706\" title=\"waveform 2\">",
"      ECG WPW tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?36/55/37754\" title=\"waveform 3A\">",
"      12-lead ECG ventricular tachycardia in ARVC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?41/5/42078\" title=\"waveform 3B\">",
"      12-lead ECG epsilon wave and T wave inversions in ARVC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?26/24/27008\" title=\"waveform 4\">",
"      Prolonged QT interval tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?42/23/43380\" title=\"waveform 5\">",
"      ECG Torsades de pointes tutorial",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=related_link\">",
"      Acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/19/17719?source=related_link\">",
"      Arrhythmic complications of mitral valve prolapse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28250?source=related_link\">",
"      Brugada syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/42/41637?source=related_link\">",
"      Bundle branch reentrant ventricular tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/19/17722?source=related_link\">",
"      Cardiac sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37641?source=related_link\">",
"      Catecholaminergic polymorphic ventricular tachycardia and other polymorphic ventricular tachycardias with a normal QT interval",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30890?source=related_link\">",
"      Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2202?source=related_link\">",
"      Clinical features of congenital long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/10/23722?source=related_link\">",
"      Clinical manifestations and diagnosis of amyloid cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/22/32106?source=related_link\">",
"      Clinical manifestations and diagnosis of arrhythmogenic right ventricular cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/16/26889?source=related_link\">",
"      Clinical manifestations and diagnosis of myocarditis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36522?source=related_link\">",
"      Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/36/36424?source=related_link\">",
"      Clinical significance and treatment of ventricular premature beats",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34874?source=related_link\">",
"      Clinical utility of cardiovascular magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/52/12101?source=related_link\">",
"      Commotio cordis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/56/14218?source=related_link\">",
"      Congenital and pediatric coronary artery abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29722?source=related_link\">",
"      Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/6/33897?source=related_link\">",
"      Diagnosis of congenital long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/3/1082?source=related_link\">",
"      Echocardiographic evaluation of the aortic valve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/12/15562?source=related_link\">",
"      Echocardiographic recognition of cardiomyopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/24/11658?source=related_link\">",
"      Electrocardiogram in the diagnosis of myocardial ischemia and infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28522?source=related_link\">",
"      Epidemiology of and risk factors for atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/20/44361?source=related_link\">",
"      Epidemiology of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/61/17370?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of the Wolff-Parkinson-White syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/56/19337?source=related_link\">",
"      Hypoxic-ischemic brain injury: Evaluation and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/24/20874?source=related_link\">",
"      Incidence of and risk stratification for sudden cardiac death after acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/26/20906?source=related_link\">",
"      Noninvasive coronary imaging with cardiac computed tomography and cardiovascular magnetic resonance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/21/30041?source=related_link\">",
"      Outcome of sudden cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/55/890?source=related_link\">",
"      Overview of sudden cardiac arrest and sudden cardiac death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/54/16233?source=related_link\">",
"      Pathophysiology and etiology of sudden cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33239?source=related_link\">",
"      Pharmacotherapy for posttraumatic stress disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27352?source=related_link\">",
"      Posttraumatic stress disorder: Epidemiology, pathophysiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/46/16106?source=related_link\">",
"      Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/36/13898?source=related_link\">",
"      Risk of sudden cardiac death in athletes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/52/35658?source=related_link\">",
"      Risk stratification for cardiac events after acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43385?source=related_link\">",
"      Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/61/19417?source=related_link\">",
"      Short QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/12/15559?source=related_link\">",
"      Sudden cardiac arrest in the absence of apparent structural heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/3/22586?source=related_link\">",
"      Ventricular arrhythmias and sudden cardiac arrest in hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/47/21241?source=related_link\">",
"      Ventricular arrhythmias in heart failure and cardiomyopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_24_4491="Thickness versus survival";
var content_f4_24_4491=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F83111&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F83111&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Thin melanoma depth of invasion and survival",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Breslow depth (mm)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Melanoma-specific survival at 20 years (percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        &lt;0.25",
"       </td>",
"       <td class=\"centered\">",
"        98.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        0.25 &ndash; 0.49",
"       </td>",
"       <td class=\"centered\">",
"        98.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        0.50 &ndash; 0.74",
"       </td>",
"       <td class=\"centered\">",
"        96.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        0.75 &ndash; 1.0",
"       </td>",
"       <td class=\"centered\">",
"        89.0",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Antonio Buzaid.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_24_4491=[""].join("\n");
var outline_f4_24_4491=null;
var title_f4_24_4492="Differential diagnosis of shock in trauma";
var content_f4_24_4492=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F63698&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F63698&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of shock in trauma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        I. Low CVP",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A. Hypovolemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        1. Hemorrhage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        a. External (compressible)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        i. Lacerations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        ii. Contusions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        iii. Fractures (partly compressible)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        b. Internal (noncompressible)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        i. Intrathoracic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        ii. Intraperitoneal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        iii. Retroperitoneal (partly compressible)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        c. Fractures (partly compressible)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2. Third spacing (eg, burns)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        B. Neurogenic (high cervical cord injury)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        II. High CVP",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A. Pericardial tamponade",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        B. Tension pneumothorax",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        C. Myocardial contusion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        III. Other diagnoses to consider",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A. Pharmacologic or toxicologic agents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        B. Myocardial infarction (severe)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        C. Diaphragmatic rupture with herniation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        D. Fat or air embolism",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_24_4492=[""].join("\n");
var outline_f4_24_4492=null;
var title_f4_24_4493="Management IRIS A";
var content_f4_24_4493=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F65960&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F65960&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    General management recommendations for specific IRIS-related syndromes*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Pathogen",
"       </td>",
"       <td class=\"subtitle1\">",
"        Most common clinical manifestations",
"       </td>",
"       <td class=\"subtitle1\">",
"        Management recommendations",
"       </td>",
"       <td class=\"subtitle1\">",
"        Prognosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        General IRIS",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Consider concurrent unmasked infection, persistent active infection, antimicrobial resistance, adverse drug reaction, and medicine nonadherence.",
"       </td>",
"       <td>",
"        Generally self-limited",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        M. tuberculosis",
"       </td>",
"       <td>",
"        <p>",
"         Pneumonia",
"        </p>",
"        <p>",
"         Lymphadenitis",
"        </p>",
"        <p>",
"         Intracranial tuberculomas",
"        </p>",
"        <p>",
"         Meningitis",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Consider the possibility of multidrug resistant TB.",
"        </p>",
"        <p>",
"         Incise and drain the initial episode of adenitis for diagnostic purposes and symptomatic relief.",
"        </p>",
"        <p>",
"         For moderate severity or CNS involvement, prednisone (1.0 mg/kg, up to 80mg daily) or dexamethasone 8-16 mg/day divided in twice daily doses and tapered after 1-2 months. Use as adjunct to anti-tuberculous therapy.",
"        </p>",
"        <p>",
"         Continue HAART&bull;.",
"        </p>",
"       </td>",
"       <td>",
"        Generally self-limited",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        M. avium complex",
"       </td>",
"       <td>",
"        <p>",
"         Lymphadenitis",
"        </p>",
"        <p>",
"         Pneumonia",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Incision and drainage or aspiration for the initial episode of adenitis.",
"        </p>",
"        <p>",
"         If illness is severe, adjunct corticosteroids (as above) in addition to standard anti-MAC therapy.",
"        </p>",
"        <p>",
"         Continue HAART.",
"        </p>",
"       </td>",
"       <td>",
"        Self-limited in the vast majority",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cryptococcus spp.",
"       </td>",
"       <td>",
"        <p>",
"         Meningoencephalitis",
"        </p>",
"        <p>",
"         Pneumonia",
"        </p>",
"        <p>",
"         Lymphadenitis",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Continue antifungal therapy.",
"        </p>",
"        <p>",
"         Adjunct corticosteroids, if illness is severe or not self-limited.",
"        </p>",
"        <p>",
"         Continue HAART&bull;.",
"        </p>",
"       </td>",
"       <td>",
"        Generally self-limited",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pneumocystis carinii",
"       </td>",
"       <td>",
"        Pneumonia",
"       </td>",
"       <td>",
"        <p>",
"         Standard course of anti-Pneumocystis antimicrobial therapy.",
"        </p>",
"        <p>",
"         Adjunct corticosteroids.",
"        </p>",
"        <p>",
"         Continue HAART&bull;.",
"        </p>",
"       </td>",
"       <td>",
"        Generally self-limited when corticosteroid therapy is used.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cytomegalovirus",
"       </td>",
"       <td>",
"        Uveitis/vitritis",
"       </td>",
"       <td>",
"        <p>",
"         Continue HAART&Delta;.",
"        </p>",
"        <p>",
"         Anti-CMV antiviral therapy if concurrent CMV retinitis is present.",
"        </p>",
"        <p>",
"         Topical, intraocular, or systemic corticosteroids in conjunction with close ophthalmologic follow-up&loz;.",
"        </p>",
"        <p>",
"         Vitrectomy may be needed if vitreomacular traction occurs.",
"        </p>",
"       </td>",
"       <td>",
"        Generally good, but long-term sight-threatening complications may occur.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Based on published clinical experience, but needs to be proven in controlled clinical trials.",
"     <br>",
"      &bull; Consider delaying HAART therapy for 1-2 months if not already begun.",
"      <br>",
"       &Delta; Consider temporarily interrupting HAART for 1-3 months if eye, neural, liver, or other organ involvement is particularly severe, progressive, and/or steroid refractory.",
"       <br>",
"        &loz; Can alternatively use topical or systemic non-steroidal anti-inflammatory agents.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_24_4493=[""].join("\n");
var outline_f4_24_4493=null;
var title_f4_24_4494="TNM staging esoph adenoCA including EGJ";
var content_f4_24_4494=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F52078&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F52078&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    TNM staging of esophageal and esophagogastric junction (EGJ) adenocarcinoma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"5\">",
"       Primary tumor (T)*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       TX",
"      </td>",
"      <td colspan=\"4\">",
"       Primary tumor cannot be assessed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T0",
"      </td>",
"      <td colspan=\"4\">",
"       No evidence of primary tumor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Tis",
"      </td>",
"      <td colspan=\"4\">",
"       High-grade dysplasia&bull;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       T1",
"      </td>",
"      <td class=\"sublist_other_start\" colspan=\"4\">",
"       Tumor invades lamina propria, muscularis mucosae, or submucosa",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       T1a",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"4\">",
"       Tumor invades lamina propria or muscularis mucosae",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       T1b",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"4\">",
"       Tumor invades submucosa",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T2",
"      </td>",
"      <td colspan=\"4\">",
"       Tumor invades muscularis propria",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T3",
"      </td>",
"      <td colspan=\"4\">",
"       Tumor invades adventitia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       T4",
"      </td>",
"      <td class=\"sublist_other_start\" colspan=\"4\">",
"       Tumor invades adjacent structures",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       T4a",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"4\">",
"       Resectable tumor invading pleura, pericardium, or diaphragm",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       T4b",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"4\">",
"       Unresectable tumor invading other adjacent structures, such as aorta, vertebral body, trachea, etc.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"5\">",
"       Regional lymph nodes (N)&Delta;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       NX",
"      </td>",
"      <td colspan=\"4\">",
"       Regional lymph node(s) cannot be assessed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       N0",
"      </td>",
"      <td colspan=\"4\">",
"       No regional lymph node metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       N1",
"      </td>",
"      <td colspan=\"4\">",
"       Metastasis in 1-2 regional lymph nodes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       N2",
"      </td>",
"      <td colspan=\"4\">",
"       Metastasis in 3-6 regional lymph nodes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       N3",
"      </td>",
"      <td colspan=\"4\">",
"       Metastasis in seven or more regional lymph nodes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"5\">",
"       Distant metastasis (M)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       M0",
"      </td>",
"      <td colspan=\"4\">",
"       No distant metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       M1",
"      </td>",
"      <td colspan=\"4\">",
"       Distant metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"5\">",
"       Histologic grade (G)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       GX",
"      </td>",
"      <td colspan=\"4\">",
"       Grade cannot be assessed - stage grouping as G1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       G1",
"      </td>",
"      <td colspan=\"4\">",
"       Well differentiated",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       G2",
"      </td>",
"      <td colspan=\"4\">",
"       Moderately differentiated",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       G3",
"      </td>",
"      <td colspan=\"4\">",
"       Poorly differentiated",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       G4",
"      </td>",
"      <td colspan=\"4\">",
"       Undifferentiated - stage grouping as G3 squamous",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"5\">",
"       Anatomic stage/prognostic groups",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\" colspan=\"5\">",
"       Adenocarcinoma carcinoma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle4\">",
"       Stage",
"      </td>",
"      <td class=\"subtitle4\">",
"       T",
"      </td>",
"      <td class=\"subtitle4\">",
"       N",
"      </td>",
"      <td class=\"subtitle4\">",
"       M",
"      </td>",
"      <td class=\"subtitle4\">",
"       Grade",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       0",
"      </td>",
"      <td>",
"       Tis (HGD)",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"      <td>",
"       1, X",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       IA",
"      </td>",
"      <td>",
"       T1",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"      <td>",
"       1-2, X",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       IB",
"      </td>",
"      <td>",
"       T1",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"      <td>",
"       3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T2",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"      <td>",
"       1-2, X",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       IIA",
"      </td>",
"      <td>",
"       T2",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"      <td>",
"       3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       IIB",
"      </td>",
"      <td>",
"       T3",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"      <td>",
"       Any",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T1-2",
"      </td>",
"      <td>",
"       N1",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"      <td>",
"       Any",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"3\">",
"       IIIA",
"      </td>",
"      <td>",
"       T1-2",
"      </td>",
"      <td>",
"       N2",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"      <td>",
"       Any",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T3",
"      </td>",
"      <td>",
"       N1",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"      <td>",
"       Any",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T4a",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"      <td>",
"       Any",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       IIIB",
"      </td>",
"      <td>",
"       T3",
"      </td>",
"      <td>",
"       N2",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"      <td>",
"       Any",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"3\">",
"       IIIC",
"      </td>",
"      <td>",
"       T4a",
"      </td>",
"      <td>",
"       N1-2",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"      <td>",
"       Any",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T4b",
"      </td>",
"      <td>",
"       Any",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"      <td>",
"       Any",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Any",
"      </td>",
"      <td>",
"       N3",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"      <td>",
"       Any",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       IV",
"      </td>",
"      <td>",
"       Any",
"      </td>",
"      <td>",
"       Any",
"      </td>",
"      <td>",
"       M1",
"      </td>",
"      <td>",
"       Any",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Note: cTNM is the clinical classification, pTNM is the pathologic classification.",
"    <div class=\"footnotes\">",
"     * At least maximal dimension of the tumor must be recorded and multiple tumors require the T(m) suffix.",
"     <br>",
"      &bull; High-grade dysplasia (HGD) includes all noninvasive neoplastic epithelia that was formerly called carcinoma in situ, a diagnosis that is no longer used for columnar mucosae anywhere in the gastrointestinal tract.",
"      <br>",
"       &Delta; Number must be recorded for total number of regional nodes sampled and total number of reported nodes with metastasis.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_24_4494=[""].join("\n");
var outline_f4_24_4494=null;
var title_f4_24_4495="Subconjunctival hemorrhage";
var content_f4_24_4495=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F51578&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F51578&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Subconjunctival hemorrhage",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 322px; height: 213px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Extravasated blood in the inferior conjunctiva.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Trobe JD, Hackel RE. Field Guide to the Eyes. Lippincott Williams &amp; Wilkins, Philadelphia 2002. Copyright &copy; 2002 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_24_4495=[""].join("\n");
var outline_f4_24_4495=null;
             